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ABSTRACT
TGFβ signaling is an important regulator in colon cancer. miRNAs regulate TGFβ
signaling at multiple levels. In this study, through a functional screening, we identified miR487b-3p and miR-656-3p, which modulate TGFβ effect in colon cancer cells. Further studies
revealed that GRM3 and VGLUT3 are their respective targets.
GRM3, a Metabotropic glutamate receptor in glutamatergic pathway is significantly
upregulated in majority of human colonic adenocarcinomas tested and colon cancer cell lines.
Knockdown of GRM3 expression or inhibition of GRM3 activation in colon cancer cells
reduces cell survival and anchorage-independent growth in vitro and inhibits tumor growth in
vivo. Mechanistically, GRM3 antagonizes TGFβ-mediated activation of protein kinase A and
inhibition of AKT. In addition, TGFβ signaling increases GRM3 protein stability and
knockdown of GRM3 enhances TGFβ-mediated tumor suppressor function. Since miR-487b3p directly targets GRM3, overexpression of miR-487b-3p mimics the effects of GRM3
knockdown in vitro and in vivo. Expression of miR-487b-3p is decreased in colon
adenocarcinomas and inversely correlates with GRM3 expression.
VGLUT3, a vesicular glutamate transporter, is also markedly upregulated in human
colonic adenocarcinomas and colon cancer cell lines. Knockdown of VGLUT3 expression in
colon cancer cells reduces cell survival and anchorage-independent growth in vitro and inhibits
tumor growth in vivo. Mechanistically, VGLUT3 antagonizes TGFβ-mediated suppression of
cell survival and clonogenicity by maintaining AKT activation. MiR-656-3p represses
VGLUT3 expression and mimics the effects of VGLUT3 knockdown in vitro and in vivo.
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Moreover, expression of miR-656-3p is decreased in colon cancer specimens and inversely
correlates with VGLUT3 expression.
This is particularly interesting and important from a therapeutic standpoint because
numerous glutamatergic signaling inhibitor, many of which have been found unsuitable for
treatment of neuropsychiatric disorders for reasons such as inability to readily penetrate blood
brain barriers. Since GRM3 and VGLUT3 are upregulated in colon cancer, but rarely expressed
in normal peripheral tissues, targeting GRM3 and VGLUT3 with such agents would not likely
cause adverse neurological or peripheral side effects, making them attractive and specific
molecular targets for colon cancer treatment.
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CHAPTER 1：INTRODUCTION
Colorectal cancer
Colorectal cancer (CRC) is a common and fatal disease. Nearly 150,000 U.S. residents are
diagnosed annually with CRC, and approximately one-third of CRC patients die from the
disease1. CRC begins as a benign adenomatous polyp, which develops into an advanced
adenoma with high grade dysplasia and then progresses to an invasive cancer. Stage I and II
tumors which are confined within the wall of the colon are curable by surgery. Combination of
surgery and adjuvant chemotherapy can increase 3-year disease free survival for up to 73% of
cases of stage III tumor. But stage IV tumors which metastasize to distant sites are usually
incurable 2. Therefore, understanding the mechanisms of CRC development and metastasis and
identifying novel targets for CRC treatment are of importance and challenge.
TGFβ and cancer
The transforming growth factor-beta (TGFβ) was discovered more than three decades ago
and was isolated as a secreted factor from sarcoma virus-infected cells

3 4

.TGFβs are 25-kDa

cytokines that play a pivotal role during mammalian development and act as a regulator of
wound healing, fibrosis, angiogenesis and differentiation of the cells. More than 40 different
members have been identified in this family. In mammalian cells, there are three TGFβ isoforms
(TGFβ1, TGFβ2, and TGFβ3), among which TGFβ 1 is the most abundant and universally
expressed isoform 5. TGFβ signaling is initiated by TGFβ binding to TGFβ receptor type II
(TGFβRII) which binds and activates TGFβ receptor type I (TGFβRI). Activated TGFβRI
subsequently phosphorylates SMAD2 and SMAD3 at the carboxyl terminal serines. Following
phosphorylation, SMAD2 and SMAD3 form heteroligomeric complexes with the co-SMAD,
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SMAD4, and accumulate in the nucleus. SMAD proteins recognize DNA sequence CAGAC,
called SMAD binding element (SBE). They also bind to some other GC rich sequences, but the
binding for those DNA sequences is weak. SMADs usually associate with other transcriptional
cofactors to achieve specific regulation of TGFβ-mediated transcription response (Fig 1.1) 6.
Other members in the TGFβ superfamily, such as bone morphogenetic proteins (BMPs), active
their signaling through other R-SMAD proteins (such as SMAD1 ,5 and 8) 7.

Fig 1.1

Figure 1.1. Schematic diagram of TGFβ signaling pathway.
On the cell membrane, TGFβ binds to the receptor II which in turn attracts and
phosphorylates TGFβ receptor I. Activated receptor I phosphorylates Smad2/3 which recruit
smad4 in the nuclear. In the nucleus, Smad complex bind to the cofactor and regulate target
genes engaged in both tumor promotion and tumor repression.

3

TGFβ/SMAD signaling is regulated by multiple mechanisms to maintain tightly controlled
TGFβ response. SMAD7 is the first described inhibitory SMAD which negatively regulates
TGFβ response by preventing access of SMAD2/3 to the kinase domain of receptor I 8,9.SMAD
7 also recruits phosphatases and ubiquitin ligases (smurf1/2) to the active TGFβ receptor I to
terminate TGFβ signaling 10. Another inhibitory SMAD, SMAD6, competes with SMAD4 for
binding to receptor activated SMAD17.
In addition to mediating the transcription of its target genes, TGFβ can also activate
GTPases (Rac1, Cdc42, RhoA and Ras), MAP kinases (JNK, p38 MAPK and ERK1/ERK2),
growth and survival promoting kinases (PI3K, AKT/PKB and mTOR) and tyrosine kinases
(FAK, Src and Abl) in different cell context 11.
In normal condition, TGFβ is released by blood platelets and various stromal components.
TGFβ is frequently present in tumor environment. Tumor infiltrating cells such as leukocytes,
macrophages, and bone marrow-derived endothelial, mesenchymal, and myeloid precursor
cells can secret TGFβ, tumor cells themselves and tumor stroma cells are sources of TGFβ too
12

. In tumors, TGFβ is a potent inducer of growth inhibition at early stages of tumorigenesis.

For example, when the tumor is still benign, TGFβ acts directly on tumor cells to suppress
tumor outgrowth by inducing expression of CDK inhibitors p15INK4B and/or p21CIP1. The
induction of p15 and p21 by TGFβ is through SMADs and other transcriptional factors like
FoxO forkhead and Sp1 13,14. Suppression of oncogenes like c-Myc and ID family of helix-loophelix transcription factors (ID1,ID2,ID3) is also observed in many cell types that are growth
inhibited by TGFβ

15,16

. TGFβ has also been shown to induce apoptosis in epithelium, liver,

immune system and tumors 17. In hepatocarcinomas, TGFβ induces apoptosis by increasing the
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interaction of Daxx protein with TGFβ RII, which further actives JNK and Fas-mediated
apoptotic pathways

18

. In many types of cells, TGFβ induces pro-apoptotic Bcl-2 family

members, Bmf and Bim, which activate Bax and induce apoptosis 19. In some other types of
cells, TGFβ suppresses the expression of anti-apoptotic proteins Bcl-XL and Bcl-2

19

. In

immune cells, TGFβ shows a strong pro-apoptotic effect by inducing expression of Src
homology 2 domain-containing 5’ inositol phosphatase (SHIP), which causes cell death of
immune cells

20

. In colon cancer cells, TGFβ antagonizes the survival pathways through

downregulation of PI3K-AKT

21

and Bcl-XL

22

. In addition, TGFβ prevents cellular

immortalization by regulating the expression of human telomerase reverse transcriptase
(hTERT) in both normal and cancer cells 23.
Mutations in the TGFβ signaling pathway occur in at least half of colorectal cancer,
commonly inactivating TGFβ RII, SMAD2, SMAD3 or SMAD4, which leads to its inability to
inhibit cell growth and induce apoptosis24-26. Mutations of TGFβ RII lead to the formation
of truncated or kinase inactive mutant forms of the receptor 27. Mutations of SMADs are mostly
due to deletions, frameshift, nonsense and missense mutations 28. Overexpression of SMAD
repressors also contributes to the inhibition of SMAD signaling. For example, SnoN, Ski, and
inhibitory SMAD family members SMAD7 have been found to be overexpressed in many
different types of cancers 29. Besides the change on TGFβ receptors and SMADs, the alteration
of other signaling pathways can also affect TGFβ signaling during tumor progression. For
instance, the Ras-Raf-MAPK pathway regulates the activation of SMAD3 by regulating its
phosphorylation 30.
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As tumor progresses, the cytostatic effects of TGFβ are often lost, and instead, TGFβ is
shown to stimulate tumor progression by inducing epithelial to mesenchymal transition (EMT),
31

stimulating angiogenesis and immunosuppression
correlated with high tumor grade and metastasis

. In some cancers, TGFβ secretion is

32

. As mentioned above, TGFβ secreted by

tumor cells and tumor stroma cells has a huge effect on immune system. It inhibits expression
and activation of interleukin-2 and its receptors and blocks its stimulation on T cells 33. TGFβ
also exerts inhibitory effect on proliferation and differentiation of T lymphocytes, lymphokineactivated killer cells, nature killer cells, neutrophils, macrophages and B cells 34. It has been
shown that TGFβ inhibits the expression of tumor cell surface major histocompatibility
complex class II antigen in a SMAD3 dependent manner 35. Taken together, TGFβ in the tumor
environment helps tumor cells to escape host immunosurveillance and contributes to tumor
progression.
Angiogenesis is essential to allow blood vessels to deliver oxygen and nutrients to tumor
cells. TGFβ signaling has been shown to be correlated with increased micro vessel density in
many types of cancers 36 37.The most common role of TGFβ on angiogenesis is to stimulate the
expression of vascular endothelial growth factor(VEGF) and connective tissue growth factors
(CTGF)

38,39

. In addition, the matrix metalloproteinase (MMPs) induced by TGFβ allows

endothelia cells to be released from the basement and migrate to the tumor site 40. Moreover,
TGFβ represses the expression of angiopoietin-1 to allow the tumor-associated blood vessels
to become more permeable 41.
EMT is an important process that cancer cells use to migrate and invade

42

. The role of

TGFβ on EMT has been well characterized. The TGFβ-SMADs canonical pathway
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transcriptionally activates EMT regulatory factors, such as SNAIL, SLUG, ZEB-2 and TWIST,
resulting in the loss of epithelial cell polarity and the increase of migration and invasion 43.
TGFβ induced EMT changes the profile of adhesion molecules and promote cancer cells to
detach from their primary site and disseminate throughout the stroma.
TGFβ significantly affects colon cancer biological behaviors. Moderate and well
differentiated colon tumors were growth inhibited by TGFβ, while, metastatic colon tumors
responded to TGFβ by invasion and proliferation44 . In the well differentiated colon tumors,
TGFβ activates its downstream targets which are important cell cycle checkpoint genes,
including p21, p17 and p15

44

. TGFβ also interacts with PI3K-AKT pathways and induce

apoptosis in colon cancer cells 21. TGFβ RII mutation is the most common alteration in colon
cancers45. Loss of TGFβ RII function grants a growth advantage for cancer cells by cooperating
with mutant Kras and Wnt signaling 46. SMAD4 is also a frequently mutated gene in TGFβ
pathway. SMAD4 is a key mediator for TGFβ induced antiproliferative response, but TGFβ
induced EMT is not dependent on SMAD447. This indicate that loss of SMAD4 function might
be an important event during colon cancer progression.
MiRNAs
MicroRNAs (miRNAs) are approximately 19–25 nucleotides long (with an average of 22
nucleotides), noncoding RNA molecules that post-transcriptionally regulate gene expression by
binding either to the 3’untranslated regions (3’UTR), 5’untranslated regions (5’UTR) or the
coding sequence of protein-encoding mRNAs 48. The region at the 5’ end of miRNAs that spans
from nucleotide position 2 to 7 is termed the 'miRNA seed'. It is crucial for target recognition.
The downstream nucleotides of miRNA (particularly nucleotide 8 and less importantly
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nucleotides 13–16) also contribute to base pairing with the targets

49

. miRNAs regulate

approximately 30–50% human genes and majority of genetic pathways. miRNA genes are
transcribed by RNA polymerase II (Pol II). The long primary transcript has a local hairpin
structure where miRNA sequences are embedded. Majority of human miRNAs are encoded by
introns of noncoding or coding transcripts, but some miRNAs are encoded by exonic regions.
The transcription of miRNAs is controlled by RNA Pol II associated transcription factors and
epigenetic regulators such as P53, MYC and other DNA/RNA binding proteins 50. Following
transcription, the primary miRNAs are processed through several steps to become mature
miRNAs. The maturation of primary miRNAs is initiated by a nuclear RNase III, called Drosha,
which forms a microprocessor with a cofactor DGCR8 and crops the stem–loop to release a
small hairpin-shaped RNA of ~65 nucleotides in length (pre-miRNA)

51

. Pre-miRNAs are

exported to the cytoplasm after processed by Microprocessor. The protein exportin 5 (EXP5;
encoded by XPO5) forms a transport complex with GTP-binding nuclear protein RAN•GTP,
which exports the pre-miRNA out of the nuclear 52. In the cytoplasm, pre-miRNAs are cleaved
by RNase III type endonuclease called Dicer, liberating a small RNA duplex 53. The small RNA
duplex is subsequently incorporated into an AGO protein to form an effector complex called
RNA-induced silencing complex (RISC). As a result, the passenger strand is quickly removed
and a mature RNA-induced silencing complex is formed 54. MiRNA biogenesis is shown in Fig
1.2. 55
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Fig 1.2

Fig 1.2. Biogenesis of miRNAs.
Pri-miRNA are transcribed by RNA polymerase II, and processed to pre-miRNA in the nucleus.
RNA splicing is also a source of pre-miRNAs. Pre-miRNAs are transported into the cytosol,
where they are pressed by Dicer to become mature miRNAs and regulate target gene expression.
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miRNAs and cancer
A significant number of miRNAs are located at genomic regions linked to cancer 56. The
first evidence of aberrant miRNA expression in human cancers was described in B-cell chronic
lymphocytic leukemia. A chromosomal deletion at the 13q14 locus resulted in the loss or
reduction of miR-15 and miR-16 expression，which are inhibitors of oncogenetic protein BCL2 57. miRNA expression can be altered through different mechanisms, including chromosomal
abnormalities, epigenetic changes, mutations and single nucleotide polymorphisms (SNPs), and
defects in the miRNA biogenesis machinery

58

. Many miRNAs reside at fragile site of the

chromosome where sister chromatin exchange, translocation, deletion, amplification happen
very frequently. miR-143 and miR145 has been found to be decreased in B cell chronic
lymphocytic leukemias and lung cancers, while miR-19-92, located at chromosome 13q31, is
found overexpressed due to chromosomal amplification in those cancers

57,59

. In addition,

epigenetic changes affect miRNAs expression as well. MiR21, miR-203 and miR-205 were
found to be overexpressed in ovarian carcinomas through hypomethylation mechanism 60. On
the contrary, decreased miR-124a expression in colon, breast, and lung cancers was attributed
to DNA hypermethylation 61.
miRNAs have been demonstrated to function as oncogenes or tumor suppressors 62. The
overexpression of miR-155 is associated with several types of lymphomas. Transgenic mice
overexpressing miR-155 developed a preleukemic lymphoproliferative disease that progressed
to B-cell leukemia and high grade lymphoma 63. Down regulation of some miRNAs might be
advantageous for cancer cells. For example, miR-17 was found to be downregulated in breast
cancers and ectopic expression of this miRNA reduced cancer cell proliferation 64.
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In cancers, miRNAs affect cell growth, proliferation, apoptosis, invasion and metastasis
by regulating genes in different signaling pathways 65. miR-221/222, miR-17-92 and miR-10625 have been reported to target negative cell-cycle regulators and promote cancer cell
proliferation 66. miR15a/16 was shown to target cyclin D1, cyclin D3, cyclin E1 and CDK6,
and their downregulation increased expression of multiple cell cycle-promoting genes 67.
Furthermore, the accumulated data on miRNA expression in tumors demonstrate that
miRNAs are promising candidates for prognostic and/or diagnostic markers. It has been shown
that the miR-222, miR-106a, and miR-17-92 cluster is associated with the degree of
differentiation of

hepatocellular carcinomas 68. High miR-21 expression was present in colon

adenomas and in tumors with more advanced TNM staging 69. Another study showed that high
level of MiR-92a was associated with decreased survival in patients with small-cell lung cancer
70

. And the expression of MiR-210 was found to be associated with poor clinical outcome of

breast cancer.71
MiRNAs and TGFβ
miRNAs and the TGFβ pathway are tightly interacted with each other. Transcription of
primary miRNAs can be dynamically regulated in response to stimulation of many growth
factors including TGFβ 72. TGFβ promotes miRNA processing by regulating miRNA DROSHA
microprocessor complex in a SMAD-depend manner 73.
Upon TGFβ treatment, alterations in expression of numerous miRNAs have been reported
in different types of cells. Expression of the miR-200 family (miR-200a, miR-200b, miR-200c,
miR-141 and miR-429) and miR-205 was markedly downregulated upon TGFβ treatment. In
addition, TGFβ suppresses expression of many other miRNAs, miR-145, Let-7d, miR-155,

11

miR-34, miR-27b, miR-29. On the contrary, there are quite a few miRNAs whose expression
is upregulated by TGFβ, for example, miR-21, miR-142, miR-146, miR17/92, etc. 74.
The TGFβ pathway is regulated by miRNAs at multiple levels. Expression of most, if not
all, members of the canonical TGFβ signaling pathway may be influenced by miRNAs. The
miR-23b cluster (including miR-23b, miR-27b and miR-24-1) suppress TGFβ signaling by
downregulating expression of SMAD3, SMAD4, and SMAD5 75. In the heart, downregulation
of miR-133 and miR-590 enhances TGFβ signaling through TGFβ RI and RII 76. In the liver,
miR-21 enhances TGFβ signaling by targeting the negative regulator SMAD7 77. While miR26a was found to target SMAD1, miR-141 and miR-200a directly inhibit TGFβ RII expression
in rat proximal tubular epithelial cells 78,79.
miRNAs can also downregulate TGFβ target genes, which ultimately affects the outcome
of TGFβ effect. The miR-106b/25 cluster (miR-106b, miR-93 and miR-25) was reported to
interfere with the tumor suppression effect of TGFβ by targeting the cell cycle inhibitor
p21Waf1/Cip1 and the pro-apoptotic protein BCL2L11 (BIM) in gastric cancer 80. BIM is also
targeted by miR-17/92 in B cells 81.
Glutamate and its signaling
Glutamate is a nonessential amino acid, a major bioenergetic substrate for proliferating in
normal and neoplastic cells. In the nervous system, glutamate is one of the key
neurotransmitters and it participates in several physiological processes such as learning,
memory, behavior and long-term potentiation and synaptic plasticity 82,83. Glutamate has been
shown to regulate proliferation, migration and survival of neuronal progenitors and immature
neurons during development of nervous system

84-86

. Moreover, its function in regulating cell

12

proliferation and migration has also been described in human brain, breast, lung and colon
cancer cell lines 87. Recent studies have demonstrated that human cancer cells release high level
of glutamate

88

, which triggers invasive tumor growth

89

. Serum glutamate level was found

correlated with Gleason Score in prostate cancer patients

90

. An analysis of freshly frozen

human samples also demonstrated that glutamate level was strikingly increased in chronic
pancreatitis and pancreatic ductal adenocarcinoma tissues compared to normal pancreatic tissue
91

.
Glutamate is stored in synaptic vesicles and released upon stimulation

92

. In mammals,

glutamatergic system is maintained by a group of glutamate transporters, which include two
super families: the excitatory amino acid transporter (EAATs) located at the plasma membrane
and the vesicular glutamate transporters (VGLUTs) located at the membrane of synaptic
vesicles. The family of VGLUTs is comprised of three highly homologous proteins VGLUT13. They transport glutamate from cytoplasm into the vesicles to be released 93. Expression of
VGLUTs is mostly complementary with limited overlap. VGLUT1 and VGLUT2 are mainly
expressed in glutamatergic neurons 94 whereas VGLUT3, encoded by SLC17A8 gene, is present
in a limited number of glutamatergic neurons in multiple brain regions and in a population of
symmetrical synapses 95. VGLUT3 is the only vesicular glutamate transporter detected in the
dendrites of striatal neurons 96. In addition to CNS, VGLUTs can be found in peripheral nervous
system (PNS) and in the glutamate-secreting non-neuronal cells of different organs, such as the
pineal gland, islets of Langerhans, intestine and stomach, bone and testes 97-100.
Glutamate signaling is initiated when glutamate binds to different type of receptors.
Glutamate receptors are divided into two groups, ionotropic glutamate receptors (iGluR) and

13

metabotropic glutamate receptors (mGluR) 101. iGluRs are quaternary ligand-gate ion channels
that allow cation influx upon glutamate binding101. Based on structural similarities iGluRs are
classified into three groups, N-methyl-D-aspartate (NMDA) receptor, a-amino-3-hydroxy-5methyl-4-isoxazolepropionic acid (AMPA) receptor, and kainate receptor subfamilies. mGluRs
belong to the superfamiliy of G-protein coupled receptors, they are classified into three
subgroups. mGluR1 and mGluR5, coupled to the phospholipase C through Gq G-protein,
belong to group I; group II consists of mGluR2 and mGluR3, whereas group III comprises of
mGluR4, mGluR6, mGluR7 and mGluR8, both of which are negatively coupled to adenylate
cyclase through Gi G-protein 102.
iGluRs have four conserved domains, including the extracellular amino-terminal (ATD),
ligand-binding (LBD), transmembrane (TMD), and intracellular carboxy-terminal (CTD)
domains. Glutamate or agonist binds to the LBD, resulting in a conformational change of the
TMD, which forms a channel in the membrane and allows calcium to pass into the cells (Fig
1.3)103.
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Fig 1.3

Figure 2.3. iGluR structure and activation.
iGluRs share the same basic structure: the N terminus (N), the amino terminal domain
(ATD), the ligand binding domain (LBD), the four transmembrane domains (TMD; numbered
1-4) and the C-terminal domain (CTD). Panel A shows the resting conformation of iGluR. The
entire protein consists 4 subunits, two of them can create a channel through the plasma
membrane. When glutamates bind to LBD (Panel B), a conformational change in TMD domain
1 causes opening of the channel where Ca2+ passes into the cell by diffusion.
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All mGluRs share a basic structure which includes a large extracellular ATD at the Nterminus, a cysteine-rich domain (CRD), a seven alpha-helical TMD and an intracellular CTD.
GluRs function when dimerized at the CRD domain, with two glutamate molecules binding to
the ATD (Fig 1.4) 103.
Fig 1.4

Figure 1.4 mGluR structure and conformational activation.
mGluR family members share the same basic structure: the N terminus (N), the amino
terminal domain (ATD), the cysteine rich domain (CRD), the seven transmembrane domains
(TMD; numbered) and the C-terminal domain (CTD). Panel A shows the resting conformation
of mGluR1a. Cysteine residues in the CRD aid in dimerization, as indicated by the S-S bond.
When glutamate bind to ATD domain (Panel B), a conformational change in the ATD causes
activation of bound G proteins.
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Group I mGluRs couple to Gq/G11 and activate phospholipase Cβ, resulting in the
hydrolysis of phosphotinositides and generation of inositol 1,4,5-trisphosphate (IP3) and
diacyl-glycerol. This classical pathway leads to calcium mobilization and activation of protein
kinase C (PKC)

104

. recently, it is been recognized that this receptor can activate many other

protein kinase pathways such as casein kinase 1, cyclindependent protein kinase 5, Jun kinase,
components of the mitogen-activated protein kinase/extracellular receptor kinase (MAPK/ERK)
and the mammalian target of rapamycin (MTOR)/p70 S6 kinase pathway 105-109. Group II and
group III receptors are coupled with Gi/0 which inhibits adenylyl cyclase. In addition, they have
been shown to activate MAPK and PI3K-AKT pathways 107.
In recent years, many studies have shown that mGluRs are the predominant mediators of
glutamatergic signaling in cancers 103. Function of mGluRs in cancer progression is first studied
in tumors of central nervous system

110

. Many evidences have also shown that mGluRs are

involved in other types of cancers 111-114. Both group I and II mGluRs have been implicated to
play a role in glioma. Inhibiting mGluR1 inhibits U87 glioma cell growth and induces apoptosis
both in vitro and in vivo by mitigating the activation of the PI3K/Akt/mTOR pathway

115

.

Another study showed that an mGluR2/3 antagonist suppressed glioma cell growth and removal
of the antagonist restored cell growth

113

. In addition, mGluRs are also studied in other non-

neuronal cancers. Chen group found that the aberrant expression of mGluR1 is the driving force
of melanomagenesis in transgenic mouse models, and mGluR1 mediated activation of the
MAPK and PI3K/AKT pathways is critical in melanoma pathogenesis

116

. An exon capture

sequencing of GPCRs study showed that in malignant melanoma specimens, somatic mutations
of mGluR3 (GRM3) (E767K, S610L,G571E and E870K) can regulate the phosphorylation of
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MEK1/2 and induce micro metastasis of

melanoma 117. In colorectal cancer, mGluR4 has been

found to be correlated with 5-Fu resistance and poor prognosis 118. The increasing evidence is
showing that glutamate signaling could be a potential target for cancer treatment.
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CHARAPTER 2：MATERIAL AND METHODS
Cell lines and reagents
The immortalized human colon epithelial cells (HCEC) were provided by Dr. Jerry
Shay119. The human colon cancer HCT116, RKO, FET, CBS, HCT116b and GEO cells were
cultured in McCoy’s 5A medium (Sigma) with 10 ng/ml epidermal growth factor (EGF), 20
µg/ml insulin, and 4 µg/ml transferrin

120

. When subjected to GFDS, cells were cultured in

medium without EGF, insulin and transferrin. Cells were maintained at 37 oC in a humidified
incubator with 5% CO2 and checked periodically for mycoplasma contamination. TGFβ and
LY341495 were obtained from R&D Systems. The miR-656-3p and miR-487b-3p inhibitor
were obtained from and Qiagen Inc. respectively. Antibody information is included in
Supplemental Table 2.1.
Western blot analysis, RT-PCR and Q-PCR assays
Whole cell lysates were prepared in RIPA buffer (1% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS, 150 mM NaCl, 10 mM Tris–HCl, pH 7.5, 5 mM EDTA and a protease
inhibitor cocktail from Sigma-Aldrich). Equivalent amounts of protein were separated by SDS–
PAGE and transferred to a PVDF membrane (Millipore). Proteins were detected using an
enhanced chemiluminescence system (Amersham Biosciences).
Expression of miR-656-3p and miR-487b-3p were determined by miScript primer assays
and miScript SYBR® Green PCR Kit from Qiagen Inc. RNU6-2 was used as an endogenous
reference gene.
Q-PCR analysis of GRM3 mRNA was performed using SYBR Green qPCR Mastermixes
(Qiagen).

The

primer

sequences

are

GCACCTCAACAGGTTCAGTGT-F

and
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TGGTGGAGTCGAGGACTTCC-R.
Expression of VGLUT1-3 and GRM2-4 mRNA was determined by RT-PCR analysis. The
primer sequences are included in Table 2.2.
Apoptosis assays
Apoptosis was detected using a DNA fragmentation ELISA kit (Roche). DNA
fragmentation ELISA assays were performed according to manufacturer’s protocol. Briefly,
cells were seeded in 96-well plates and subjected to growth factor deprivation stress (GFDS)
or treated with TGFβ. The cells were stained with MTT to determine cell numbers or lysed for
the ELISA assays to determine apoptosis. The relative apoptosis was determined by dividing
ELISA values by MTT values of each sample.
Soft agarose assays
Cells were seeded in culture medium containing low melting point agarose (Thermo
Scientific) at a density of 3,000 cells per well in 6-well plates. Two weeks later, colonies were
stained with 1% iodonitrotetrazolium violet (Sigma-Aldrich). Visible colonies were counted.
Plasmids construction and lentiviral infection
The miR-656 and miR-487b precursor-expressing lentiviral vector, pCDH-CMV, was from
SBI. ShRNAs targeting GRM3 or VGLUT3 were cloned into FSIPPW lentiviral vector. The
targeting sequences of VGLUT3 are VGLUT3 sh2 5-GCTGTAGGATTTAGTGGCTTCGCTA3, VGLUT3 sh3 5-CCCAGAATTGTGAAGTCCAGAAGAA-3. pCDF1-VGLUT3 was
purchased from Harvard plasmid, provided by David E Root group. Clone: HsCD00421938,
PMID 21706014. The targeting sequences of GRM3 was described previously

117

CAGAACATGGAAATAACCATT-3and sh2, 5- GCCTGTTTCCTATTAACGAAA-3

: sh1, 5-
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SMAD2 shRNA and SMAD3 shRNA are 5-GCACTTGCTCTGAAATTTG-3 and 5GGATTGAGCTGCACCTTGAATG-3

respectively.

PKACα

shRNA

was

described

previously121 . pCDF1-GRM3 WT was a gift from Yardena Samuels (Addgene #31798).
293 packaging cells were co-transfected with pPackH1 packaging plasmid mix (SBI) and
the lentiviral vectors using Fugene HD (Promega). Viruses were harvested 48 hours later and
used to infect target cells.
Luciferase Assays
The predicted miR-656-3p recognition sites in the 3’UTR of VGLUT3 and corresponding
mutated sequences were synthesized and cloned into psiCHECK™-2 (Promega) downstream
of Renilla reporter gene. The predicted miR-487b-3p recognition sites in the 3’UTR of GRM3
was synthesized and cloned in the same vector. The reporter was transfected into cells and
luciferase activity was measured 48 hrs later using Dual-Luciferase Reporter Assay (Promega).
Values were normalized with firefly luciferase activity.
In vivo xenograft model
Animal experiments were approved by University of Nebraska Medical Center (UNMC)
Institutional Animal Care and Use Committee. CBS cells (4 x 106) expressing a control vector,
miR-487b precursor, a scrambled shRNA or GRM3 shRNAs and HCT116 cells (2 x 106)
expressing a control vector, miR-656 precursor, a scrambled shRNA or VGLUT3 shRNAs were
injected into the flank of 4-6 week old male athymic nude mice on both sides (Harlan
Laboratories). There were 8 mice and 16 tumors in each experimental group. Tumor volumes
(V) were calculated by the formula V = W2 × L × 0.5, where W represents the largest tumor
diameter and L represents the next largest tumor diameter. Upon termination of the experiments,
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tumors were dissected out and photographed on the same scale.
IHC staining of GRM3/VGLUT3 in xenograft tumors and human patient samples
Human sample study was performed with the approval of Institutional Review Board.
TMAs consisting of triplicates of 1 mm cores of colon adenocarcinomas and adjacent normal
tissues of patients treated at UNMC in 2008 and 2009 were obtained from tissue core.
IHC staining was performed in paraffin slides using Novolink™ Min Polymer Detection
System (Leica) following manufacture’s instruction. Briefly, slides were subjected to antigen
retrieval using Novocastra Epitope Retrieval Solutions, pH6, followed by incubation with an
anti-VGLUT3 or anti-GRM3 antibody overnight at 4 °C. Slides were developed with DAB
after incubation with Novolink polymer. Finally, slides were counterstained with hematoxylin.
The slides were scanned with IScan Coreo (Ventana Medical Systems, Inc). The staining
intensity of epithelial cells was quantified with Imagescope Software (Aperio Technologies,
Inc.).
TUNEL assay and Ki67 staining
Formalin-fixed paraffin embedded (FFPE) tissue blocks of xenograft tumors were stained
for Ki67 using Novolink™ Min Polymer Detection System (Leica). TUNEL staining was
performed using Trevigen In Situ Apoptosis Detection Kit following manufacturer’s
instruction. Three tumors from each group were analyzed. Ten histologically similar fields were
randomly selected from each slide for analysis. Apoptosis and proliferation of tumor cells was
determined quantitatively by counting the numbers and calculating the percentage of positively
stained cells for TUNEL and Ki67 at 20x magnification respectively.
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In Situ hybridization
The double DIG labeled probe for miR-487b-3p and miR-656-3p and hybridization kit
were purchased from Exiqon. Hybridization was performed following Exiqon’s protocol.
Briefly, tissues were deparaffinized and digested with proteinase K (15 μg/ml; Exiqon) for 10
min at 37°C. Slides were incubated in hybridization buffer with 40 nM probe (miR-487b-3p
5DigN/AAGTGGATGACCCTGTACGATT/3Dig_N/,

miR-656-3p

5DigN/

AGAGGTTGACTGTATAATAT /3Dig_N/) in a humidified chamber at 45°C overnight. Slides
were then blocked with anti-digoxigenin-alkaline phosphatase antibodies (Roche) at 1:800
dilution for 1 hr and stained with AP substrate (NBT/BCIP tablet, Roche) at 30°C for 6 hrs. The
nuclei were counterstained with nuclear fast red (Sigma). The slides were scanned with IScan
Coreo (Ventana Medical Systems, Inc). The staining intensity of epithelial cells was determined
using Image-Pro Plus (Media Cybernetics. Inc).
Transwell assays
Cells were seeded onto the upper surface of 8-µm pore, 6.5 mm polycarbonate filters
(Corning Costar Corp.) in medium without growth factors or serum, allowed to migrate towards
medium with 10% FBS for 18 hrs and stained with MTT. The cells on the upper surface of the
filter were removed with a cotton swab, and those migrated to the underside were dissolved in
DMSO. Absorbance was read at 570 nm.
Statistical analysis
Statistical analyses were performed using Bonferroni two-sided t-test, two-way ANOVA
or Student’s t-test. *P < 0.05, ** P < 0.01, *** P < 0.001.
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Table 2.1 Antibodies
Antibodies

Companies

Western blots

IHC

anti-PARP

Cell Signaling # 9542S

1:1000

anti-pAKT S473

Cell Signaling # 9271S

1:1000

anti-CREB

Cell Signaling # 9197S

1:1000

anti-pCREB

Cell Signaling # 9198S

1:1000

anti-AKT

Cell Signaling # 4691S

1:1000

anti-SMAD2

Cell Signaling # 5339S

1:1000

anti-SMAD3

Cell Signaling # 9523S

1:1000

anti-pSMAD1/5

Cell Signaling # 9516S

1:1000

anti-ERK

Santa Cruz sc-514302

1:1000

anti-pERK

Santa Cruz sc-7383

1:1000

anti-Actin

Thermo Scientific MA5-15739

1:5000

anti-GAPDH

Thermo Scientific MA1-16757

1:5000

anti-Ki67

Thermo Scientific MA5-14520

anti-GRM3

Alomone labs AGC-012

1:1000

1:500

anti-VGLUT3

Alomone labs AGC-037

1:1000

1:500

1:1000
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Table 2.2. Primers

Primers

sequence
5-GAGAAGGTGGGCCGTGCCATGAG-3

GRM2
5-CGCTGCCTGCCCGCAGATAGGT-3
5-GCTCCAACATCCGCAAGTCCTA-3
GRM3
5-TGTCAATGGCCAGGTGCTTGTC-3
VGLUT3

5-TGGGCTGGGATTCTGCATTT-3
5-TGACAAGAGACCCACACTTAGAC-3

VGLUT2

5-TGGCAACCACCTCCTTTTGT-3
5-CATAGTGGACTAGGGCAGCG-3

VGLUT1

5-CAGGAAGGCGCGAGACATTGGAG-3
5-AGTGAACACGGGCTGCTGAAGGGA-3

VGLUT3 sh2

GCTGTAGGATTTAGTGGCTTCGCTA

VGLUT3 sh3

CCCAGAATTGTGAAGTCCAGAAGAA
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CHAPTER 3: MIRNA LIBRARY SCREENING.
Accumulating reports have shown that miRNAs are important players in many types of
human cancers. TGFβ is an important regulator in colon cancer. Functional genetic screening
is a systematic, non-biased and powerful approach for gene discovery. Here we used a
microarray based miRNAs screening approach and identified some nova miRNAs that involved
in TGFβ function in colon cancer cells.
The functional screening is described in Figure 3.1. A library of 560 miRNAs expression
vectors was introduced into FET cells, after recovery from infection, cells were seeded into
10cm dish at a density of 9000 cell per well in the presence of 10ng/ml TGFβ (eight replicates).
The empty vector-transduced cells were plated at the same density as a negative control, and
TGFβ response defect FET Dominant negative RII cells as positive control. Two weeks after
treatment, colonies were harvested and a second round of TGFβ selection was performed. By
the end of two rounds selection, survived cells were harvested and genome DNA was extracted
from each plate. The integrated miRNAs were amplified from genomic DNA by PCR using
specific primers. The PCR product was purified and labeled with cy3 as end sample. PCR
product from vector control cells which underwent two round of colony formation without any
TGFβ treatment will be labeled with cy5 as initial sample. Equal amount of initial sample and
end sample were mixed and hybridized to the customized microarray. Microarray data was
analyzed by Agilent, the average fold change of each miRNAs compared to control was
calculated, p value was calculated by Student t test. As shown in Table 3.1, some miRNAs are
enriched while some others are significantly dropped out after TGFβ selection. We then focused
on the dropped out miRNAs which can potentially make FET cells sensitive to TGFβ for future
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studies.
We then used DIANA miPath to look for the common pathways that are regulated by the
miRNAs we identified. Interestingly we found that glutamatergic pathway is highly regulated
by those miRNAs. Many studies have shown the importance of glutamatergic pathway in
cancers. GRM3 and VGLUT3 are two important components in glutamatergic pathway, they
are also targets of the miRNAs we identified. So, we hypothesize that, GRM3 and VGLUT3
might be very important regulators of colon cancer tumorigenesis and TGFβ function.
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Fig 3.1

Figure 3.1 workflow of miRNAs screening in FET cells using TGFβ.
Table 3.1

Table 3.1 List of increased and decreased miRNAs from screening
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CHAPTER 4 ： THE MIR-487B-3P/GRM3/TGFΒ SIGNALING AXIS IS AN
IMPORTANT REGULATOR OF COLON CANCER TUMORIGENESIS
INTRODUCTION
Glutamate functions as a major excitatory neurotransmitter in mammalian central nervous
system. Glutamate signaling is mediated by two classes of glutamate receptors, ionotropic and
metabotropic receptors

122

. Metabotropic receptors (mGluR), a group C family of G-protein-

coupled receptors (GPCRs), consist of eight members, classified into three subtypes

123,124

.

Group I receptors (mGluR1 and 5) are coupled to phospholipase C leading to activation of
protein kinase C, whereas group II (mGluR2 and 3) and group III (mGluR4, 6, 7 and 8)
receptors are negatively coupled to adenylyl cyclase, inhibiting production of cyclic AMP
(cAMP)

102

. Although glutamatergic system is mainly restricted to the CNS, expression of

functional glutamate receptors has been reported in non-neuronal peripheral cells such as skin
and pancreatic islets

125,126

. Furthermore, studies have revealed that glutamate signaling is

dysregulated and may play a role in cancer 118,127.
GRM3 is the gene encoding mGluR3, which is frequently mutated in melanoma. Mutant
GRM3 selectively activates MEK, leading to increased anchorage-independent growth and
migration117. Activation of GRM3 has been reported to BMP signaling and sustain tumorigenic
potential of glioma-initiating cells128. Pharmacological blockade of GRM3 reduced growth of
glioma cells in vitro and in vivo 113,129. These studies suggest that GRM3 plays a role in cancer
and could be a potential target for cancer treatment.
TGFβ signaling plays a dual role in cancer. While studies show that TGFβ promotes
metastasis and is associated with worse prognosis130,131, others demonstrate that it suppresses
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tumorigenicity and metastasis 132-135 and that loss or reduction of TGFβ signaling is associated
with development of metastasis 136,137. In genetically engineered mouse models, inactivation of
TGFβ signaling increases malignancy and invasiveness of intestinal tumors of Apc mutant mice
138-141

.

miRNAs are a group of small non-protein coding RNAs evolutionarily conserved

142

.

MiRNAs suppress expression of gene targets at the posttranscriptional level through sequencespecific interaction with the 3’-untranslated regions (UTR), leading to translation inhibition or
mRNA degradation 48. Alterations in miRNA expression are found to be associated with many
human cancers 79.
Here we demonstrate that GRM3 expression is significantly upregulated in majority of
human colonic adenocarcinomas tested and colon cancer cell lines. Knockdown of GRM3
expression or pharmacological blockade of GRM3 in colon cancer cells reduces cell survival
and anchorage-independent growth in vitro and inhibits tumor growth in vivo.
Mechanistically, GRM3 antagonizes TGFβ-mediated activation of protein kinase A (PKA) and
inhibition of AKT activation. In addition, TGFβ signaling increases GRM3 protein stability and
knockdown of GRM3 expression enhances TGFβ-mediated tumor suppressor function. Further
studies indicate that GRM3 is a direct target of miR-487b-3p and that miR-487b-3p mimics the
effects of GRM3 knockdown in colon cancer cells in vitro and in vivo. Expression of miR487b-3p is decreased in colon adenocarcinomas and inversely correlates with GRM3
expression. Taken together, these studies indicate that the miR-487b-3p/GRM3/TGFβ signaling
axis is an important regulator of colon cancer tumorigenesis and that upregulation of GRM3 is
a functionally important molecular event in colon cancer. Therefore, GRM3 is a promising
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molecular target for colon cancer treatment. This is particularly interesting and important from
a therapeutic standpoint because numerous metabotropic glutamate receptor antagonists are
available 143(37), many of which have been found unsuitable for treatment of neuropsychiatric
disorders due to their inability to readily penetrate blood brain barriers. Since GRM3 is
upregulated in colon cancer, but rarely expressed in normal peripheral tissues, targeting GRM3
with such agents would not likely cause adverse neurological or peripheral side effects, making
GRM3 an attractive and specific molecular target for colon cancer treatment.
RESULTS
Expression of GRM3 is markedly increased in colon cancer specimens.
Although it has been implicated that GRM3 is an important player in melanoma and glioma
107, 128,120

, it is unknown whether GRM3 plays a role in colon cancer. GRM3 expression was

therefore examined in human specimens using immunohistochemistry (IHC) analysis.
Verification of the anti-GRM3 antibody is shown in Fig. 3c. Tissue micro-arrays (TMAs)
consisting of 29 normal colon and 65 colon adenocarcinomas were analyzed. Mouse brain
tissue was used as a positive control. GRM3 expression was very low in normal colon
epithelium, but increased significantly in colon tumors (Fig. 4.1a). Quantification showed that
the average intensity of GRM3 staining and percentage of GRM3 positive cells were
approximately 5.5-fold and 3.8-fold higher respectively in tumors than in normal colon (Fig.
4.1b & 4.1c). In addition, GRM3 expression was increased in more than 90% of colon tumors
examined (Fig. 4.1b & 4.1c). These results demonstrate that GRM3 expression is upregulated
in majority of colon adenocarcinomas.
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Fig 4.1

Figure 4.1. GRM3 expression is elevated significantly in colon cancer specimens.
a, Immunohistochemistry staining of GRM3 was performed in normal colon and colon
adenocarcinomas. Mouse brain tissue stained with the anti-GRM3 antibody in the absence or
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presence of a specific blocking peptide was used as a positive and negative control respectively.
Representative images are shown. Scale bars, 100 µm. b&c, Quantification of GRM3 staining
intensity (b) and percentage of GRM3 positive cells (c) was performed. The values of individual
samples are shown. Error bars indicate SEM of the values. *** P < 0.001.
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GRM3 is critical for tumor growth in vivo.
These observations prompted us to investigate whether GRM3 plays a functional role in
colon cancer. A panel of human colon cancer cell lines and an immortalized human colon
epithelial cell line, HCEC119, were used. HCT116 and RKO cells are defective in TGFβ
signaling due to lack of TGFβ RII 144. HCT116b cells were isolated from the same colon tumor
as HCT116, but displayed much lower metastatic potential 145. FET cells, isolated from a well
differentiated colon tumor, are sensitive to TGFβ-mediated growth inhibition and apoptosis 21.
CBS and GEO cells are partially responsive to TGFβ due to low TGFβ RII and RI expression,
respectively

146

. HT29 cells do not express SMAD4 due to mutations

147

. All cell lines bear

either KRAS or BRAF mutations, and all except RKO 148 have mutated APC or β-catenin.
GRM3 expression was much higher in colon cancer cells than in HCECs (Fig. 4.2a, left),
consistent with the results from human specimens. However, GRM3 mRNA levels were similar
between HCECs and most of colon cancer cell lines (Fig. 4.2a, middle and right), suggesting
that upregulation of GRM3 may be through post-transcriptional mechanism(s). Of note,
expression of GRM2, the other member of group II metabotropic glutamate receptors, was
almost undetectable in all cell lines (Fig. 4.2a, middle). Mouse brain tissue was used as a
positive control. These results indicate that expression of GRM3 but not GRM2 is increased in
colon cancer cells.
To determine GRM3 function, its expression was knocked down in FET, CBS and HCT116,
three colon cancer cell lines with different genetic background. Each of two independent
shRNAs (sh1 and sh2) reduced GRM3 expression by more than 90% as compared to a
scrambled shRNA and had no effect on GRM2 expression (Fig. 4.2b, data not shown).
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Knockdown of GRM3 increased sensitivity to growth factor deprivation stress (GFDS)-induced
apoptosis, reflected by enhanced PARP cleavage (Fig. 4.2c) and increased apoptosis in DNA
fragmentation assays (Fig. 4.2d). In addition, GRM3 knockdown decreased anchorageindependent growth (Fig. 4.2e,) and inhibited motility and migration (Fig. 4.2f).

Fig 4.2

Figure 4.2. GRM3 expression is upregulated in colon cancer cells.
a, GRM3 expression was determined in colon cancer cell lines and HCECs by western blot
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analysis (left). GRM2 and GRM3 mRNA expression was determined by RT-PCR assays.
Mouse brain tissue was used as a positive control (right). GRM3 mRNA expression was
determined by Q-PCR assays (lower). b, GRM3 expression was knocked down by two shRNAs.
c&d, Control or GRM3 knockdown cells were subjected to GFDS. Cleaved PARP (c) and
apoptosis (d) were determined. e, Colony numbers were determined in soft agarose assays of
control or GRM3 knockdown cells. f, Cell motility and migration were determined in Transwell
assays of control or GRM3 knockdown HCT116 cells. The data are presented as the mean ±
SD of three replications. ** P < 0.01.
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We next examined the effect of GRM3 knockdown in vivo. Mice were subcutaneously
injected with CBS cells stably expressing a scrambled shRNA or GRM3 shRNAs. Xenograft
tumor growth curves showed that tumors of GRM3 shRNA-expressing cells (designated GRM3
shRNA tumors) grew at a significantly lower rate than those of control cells (designated control
tumors) (Fig. 4.3a). As a result, GRM3 shRNA tumors were much smaller than control tumors
(Fig. 4.3b). IHC staining confirmed GRM3 knockdown in GRM3 shRNA tumors and verified
the specificity of the anti-GRM3 antibody (Fig. 4.3c). TUNEL and Ki67 staining showed much
more apoptotic cells and fewer proliferative cells in GRM3 shRNA tumors than in control
tumors (Fig. 4.3d). These results indicate that knockdown of GRM3 inhibits tumor growth in
vivo and that this inhibitory effect is a combined result of increased apoptosis and suppressed
proliferation.
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Fig 4.3

Figure 4.3. GRM3 mediates tumor growth in vivo. a, Xenograft tumor growth curves of CBS
control and GRM3 shRNA-expressing cells are shown. n=16. b, Images of tumors at the
endpoint of experiments are shown. The pictures were taken on the same scale with the ruler
with each tumor (Fig. S9). c, Representative images of GRM3 staining in xenograft tumors are
shown (left). Quantification of staining intensity and percentage of GRM3 positive cells was
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performed (right). d, Representative images of TUNEL and Ki67 staining are shown (upper).
Percentage of positive staining cells was determined (lower). Scale bars, 100 µm. The data are
presented as the mean ± SD. *P < 0.05, ** P < 0.01.
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A GRM3 antagonist mimics GRM3 knockdown in vitro and in vivo.
LY341495 is a potent and selective antagonist of GRM2/3

149

. As shown in Fig. 4a a,

LY341495 reduced colony formation of HCT116 cells in soft agar. When mice subcutaneously
injected with HCT116 cells were treated with LY341495, tumors grew at a slower rate than
those treated with vehicle control (Fig. 4.4b). Therefore, tumors were markedly smaller in
LY341495-treated group than in control group (Fig. 4.4c). TUNEL and Ki67 staining showed
that LY341495 increased apoptotic cells and decreased proliferative cells (Fig. 4.4d). These
results indicate that pharmacological blockade of GRM3 reduces anchorage-independent
growth in vitro and tumor growth in vivo.
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Fig 4.4

Figure 4.4. The GRM3 antagonist inhibits tumor growth in vivo. a, Colony numbers were
determined in soft agarose assays of control or LY341495-treated HCT116 cells. b, Xenograft
tumor growth curves of HCT116 cells treated with LY341495 or vehicle are shown. n=14. c,
Images of tumors at the endpoint of experiments are shown. d, Representative images of
TUNEL and Ki67 staining are shown (left). Percentage of positive staining cells was
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determined (right). Scale bars, 100 µm. The data are presented as the mean ± SD. *P < 0.05,
** P < 0.01.
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GRM3 antagonizes TGFβ to regulate cell survival through the PKA/AKT signaling axis.
GRM3 is negatively coupled to adenylyl cyclase, inhibiting production of cAMP. Since
cAMP activates PKA, which inhibits AKT activation, activation of PKA and AKT was
determined. PKA activity assays showed that knockdown of GRM3 increased PKA activity
(Fig. 4.5a). Phosphorylation of CREB, a target of PKA

150

, was also used to indicate PKA

activity. Knockdown of GRM3 increased pCREB and decreased pAKT (Fig. 4.5b, left and Fig.
4.5c). Treatment with LY341495 or forskolin, a PKA activator, showed similar effect (Fig. 4.5b,
middle). Complementarily, overexpression of GRM3 reduced pCREB and increased pAKT
(Fig. 4.5b, right). These results indicate that GRM3 inhibits PKA and activates AKT in colon
cancer cells.
To determine whether PKA is involved in GRM3-mediated cell survival, the PKA catalytic
α subunit (PKACα) was knocked down in FET cells
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. GRM3 knockdown-induced PKA

activation and AKT inhibition were abrogated (Fig. 4.5d, right). Consequently, knockdown of
PKACα attenuated GRM3 knockdown-mediated increase of apoptosis under GFDS (Fig. 4.5e).
These results indicate that GRM3 knockdown inhibits AKT and suppresses cell survival
through PKA activation.
Unlike GRM3’s coupling to cAMP, TGFβ activates PKA independent of cAMP, which
inhibits AKT and suppresses cell survival. We confirmed TGFβ effect on pCREB and pAKT in
FET cells (Fig. 4.5d, left). Since GRM3 knockdown and TGFβ activate PKA independently, we
determined whether combination of both would further activate PKA and inhibit AKT. The
results showed that GRM3 knockdown and TGFβ treatment concomitantly led to additional
increase in pCREB and decrease in pAKT (Fig. 4.5d, left). As a result, when cells were treated
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with TGFβ under GFDS for 14 hours, TGFβ had little effect in control cells but induced
apoptosis in GRM3 knockdown cells (Fig. 4.5f). In addition, GRM3 knockdown sensitized FET
cells to TGFβ-mediated inhibition of anchorage-independent growth (Fig. 4.5g). These results
indicate that GRM3 antagonizes TGFβ-mediated tumor suppressor function and that GRM3
knockdown enhances TGFβ effects.
To determine the mechanism underlying collaborative effect of TGFβ and GRM3
knockdown on PKA/AKT activation, cell survival and anchorage-independent growth, we
investigated whether GRM3 mediates TGFβ signaling and found that GRM3 knockdown had
no effect on expression of SMAD2, SMAD3, SMAD4 or on canonical TGFβ signaling (data
not shown). However, TGFβ increased GRM protein expression in FET and CBS cells (Fig.
4.5h, left and middle) while had little effect on GRM3 mRNA (Fig. 5i). Inactivation of TGFβ
signaling by a dominant negative TGFβ RII (DNRII) in FET cells abrogated TGFβ effect on
GRM3 expression (Fig. 4.5h, right). Time course experiments showed that TGFβ increased
GRM3 expression as early as 30 minutes (Fig. 4.5j), suggesting that TGFβ may increase GRM3
protein stability. Treatment with cycloheximide indicated that TGFβ markedly increased the
half-life of GRM3 protein (Fig. 4.5k). Moreover, knockdown of SMAD2 or SMAD3 attenuated
TGFβ-induced GRM3 protein expression but had little effect on GRM3 mRNA levels (Fig.
4.5l), indicating that SMAD2/3 contributes to TGFβ-mediated GRM3 protein expression.
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Fig 4.5

Figure 4.5. GRM3 antagonizes TGFβ-mediated activation of PKA/AKT. a, PKA activity
was determined in FET, HCT116 and CBS cells. b, pCREB, and pAKT were determined in
FET control and GRM3 knockdown cells (left), FET cells treated with LY341495 or forskolin
(middle) and vector- or GRM3-expressing FET cells (right). c&d, pCREB, and pAKT were
determined in HCT116 and CBS control and GRM3 knockdown cells (c) and FET control and
PKACα KD cells each infected with GRM3 sh2 or treated with 4 ng/ml TGFβ or both (d). e,
PKACα was knocked down in FET control or GRM3 knockdown cells. Cells were subjected
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to GFDS for 24 hrs. Cleaved PARP (upper) and apoptosis (lower) were determined. f, FET
control or GRM3 knockdown cells were treated with 4 ng/ml TGFβ under GFDS for 14 hrs.
Cleaved PARP (upper) and apoptosis (lower) were determined. g, Colony numbers were
determined in soft agarose assays of FET control or GRM3 knockdown cells treated with 0.5
ng/ml TGFβ. h, Cells were treated with 4 ng/ml TGFβ for 6 hrs. GRM3 expression was
determined by western blot assays. i, FET cells were treated with 4 ng/ml TGFβ for 6 hrs.
GRM3 mRNA was determined by RT-PCR assays. j, FET cells were treated with 4 ng/ml TGFβ
for the indicated time. GRM3 expression was determined by western blot assays. k, FET cells
were treated with cycloheximide in the presence or absence of TGFβ. GRM3 expression was
determined by western blot assays. l, Expression of Smad2 or Smad3 was knocked down
individually in FET cells (left). Cells were treated with TGFβ. GRM3 protein and mRNA
expression was determined by western blot assays (middle) and RT-PCR analysis (right)
respectively. The data are presented as the mean ± SD of three replications. * P < 0.05, ** P <
0.01.
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MiR-487b-3p regulates GRM3 expression in colon cancer cells.
Although TGFβ increases GRM3 expression (Fig. 4.5h), it cannot fully explain ubiquitous
upregulation of GRM3 expression in colon cancer cell lines regardless of their response to
TGFβ signaling (Fig. 4.2a, left). Since GRM3 expression may be regulated posttranscriptionally (Fig. 4.2a), we turned our attention to miRNAs, which function as posttranscriptional regulators of mRNA expression and/or translation. In the previous study we have
identified several miRNAs that are potential regulators of TGFβ and colon cancer. We
performed an in silico search for putative miRNA-binding sites in the 3’UTR of human GRM3
mRNA using TargetScan
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, PicTar

153

and miRanda-mirSVR154. Among miRNA candidates

conserved between human and mouse, miR-487b-3p was identified as a potential regulator of
GRM3. Q-PCR assays indicated that expression of miR-487b-3p was much lower in colon
cancer cell lines than in HCECs (Fig. 4.6a), suggesting that decreased miR-487b-3p expression
may contribute to upregulated GRM3 expression in colon cancer cells.
To demonstrate that miR-487b-3p regulates GRM3 expression, miR-487b precursor was
stably infected into FET and CBS cells. As a result, expression of mature miR-487b-3p was
significantly increased (Fig. 4.6b, left). Complementarily, a chemically synthesized miR-487b3p inhibitor markedly reduced endogenous miR-487b-3p expression (Fig. 4.6b, right).
Overexpression of miR-487b-3p decreased GRM3 protein expression whereas the inhibitor
increased GRM3 protein expression (Fig. 4.6c, left). However, GRM3 mRNA expression was
not affected (Fig. 4.6c, right). These results indicate that miR-487b-3p suppresses GRM3
expression by inhibiting its translation. To determine whether GRM3 is a direct target of miR487b-3p, 3’-UTRs of GRM3 containing potential miR-487b-3p recognition element or mutated

47

seed sequence (Fig. 4.6d, left) was cloned into a luciferase construct. Luciferase assays revealed
that miR-487b-3p repressed wild type but not mutant 3’-UTRs of GRM3 (Fig. 4.6d, right).
These results indicate that GRM3 is a direct target of miR-487b-3p. Of note, miR-487b-5p did
not target GRM3 (Fig. 4.10).
MiR-487b-3p regulates PKA/AKT activation and mimics GRM3 knockdown effect in
colon cancer cells.
Similar to GRM3 knockdown, miR-487b-3p enhanced PKA activity (Fig. 4.6e), increased
pCREB and decreased pAKT (Fig. 4.6f). MiR-487b-3p-expressing cells displayed increased
apoptosis under GFDS (Fig. 4.6g) and decreased anchorage-independent growth (Fig. 4.6h
and ), indicating that miR-487b-3p mimicked the effect of GRM3 knockdown. In contrast, the
miR-487b-3p inhibitor decreased GFDS-induced apoptosis (Fig. 4.6i).
To determine whether miR-487b-3p-mediated effect could be reversed by restoration of
GRM3 expression, GRM3 cDNA was infected into miR-487b-3p-expressing cells (Fig. 4.6j).
Ectopically expressed GRM3 is resistant to miR-487b-3p inhibition due to the lack of 3’-UTR.
Restored GRM3 expression reversed miR-487b-3p-mediated increase of apoptosis (Fig. 4.6k).
These results indicate that miR-487b-3p sensitizes colon cancer cells to GFDS-induced
apoptosis through down-regulation of GRM3.
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Fig 4.6

Figure 4.6. GRM3 is a direct target of miR-487b-3p. a, Expression of miR-487b-3p was
determined in HCECs and colon cancer cells by Q-PCR assays. b, Expression of miR-487b-3p
was determined after infection with miR-487b precursor (left) or transfection with the miR487b inhibitor (right). c, GRM3 expression was determined by western blot assays (left) and
by RT-PCR assays (right) after infected with miR-487b precursor or transfected with the miR487b-3p inhibitor. d, The predicted miR-487b-3p recognition site in the 3’UTR of GRM3 and
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corresponding mutated sequences are indicated by lines (left). After transfection with psiCheck2 constructs containing the wild type (Wt) or mutant (Mut) sequences, luciferase assays were
performed in FET control and miR-487b-3p expressing cells (right). e, PKA activity was
determined in colon cancer cells. f, pCREB and pAKT were determined in vector- or miR487b-3p-expressing FET and CBS cells. g, Vector- or miR-487b-3p-expressing FET and CBS
cells were subject to GFDS for 24 and 48 hrs respectively. Cleaved PARP (upper) and apoptosis
(lower) were determined. h, Colony numbers were determined in soft agarose assays of vectoror miR-487b-3p-expressing FET and CBS cells. i, FET and HCT116b cells transfected with the
miR-487b-3p inhibitor were subjected to GFDS for 24 or 48 hrs respectively. Cleaved PARP
(upper) and apoptosis (lower) were determined. j&k, GRM3 was ectopically expressed in miR487b-3p-expressing FET and CBS cells (j), which were subjected to GFDS for 24 and 48 hrs
respectively. Cleaved PARP (k, upper) and apoptosis (k, lower) were determined. The data are
presented as the mean ± SD of three replications. ** P < 0.01, *** P < 0.001.
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To demonstrate that miR-487b-3p enhances TGFβ-mediated tumor suppressor function,
FET cells were treated with TGFβ under GFDS for 14 hours. TGFβ induced apoptosis in miR487b-3p-expressing cells but not in control cells (Fig. 4.7a). In addition, TGFβ inhibited
anchorage-independent growth by 96% in miR-487b-3p-expressing cells but only by 50% in
control cells (Fig. 4.7b). Restoration of GRM3 expression reversed miR-487b-3p-mediated
sensitization to TGFβ-induced apoptosis (Fig. 4.7c). Complementarily, FET cells were treated
with TGFβ under GFDS for 24 hours. While TGFβ induced apoptosis in control cells, the miR487b-3p inhibitor attenuated TGFβ-induced apoptosis (Fig. 4.7d). These results indicated that
miR-487b-3p enhances TGFβ-induced apoptosis by repressing GRM3 expression and that
inhibition of miR-487b-3p antagonizes TGFβ effect.
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Fig 4.7

Figure 4.7. MiR-487b-3p mimics the effect of GRM3 knockdown in colon cancer cells. a,
Vector- or miR-487b-3p-expressing FET cells were treated with 4 ng/ml TGFβ under GFDS for
14 hrs. Cleaved PARP (left) and apoptosis (right) were determined. b, Colony numbers were
determined in soft agarose assays of vector- or miR-487b-3p-expressing FET cells treated with
0.5 ng/ml TGFβ. c, MiR-487b-3p-expressing FET cells were infected with GRM3 cDNA and
treated with 4 ng/ml TGFβ under GFDS for 14 hrs. Cleaved PARP (left) and apoptosis (right)
were determined. d, FET cells transfected with the miR-487b-3p inhibitor were treated with 4
ng/ml TGFβ under GFDS for 24 hrs. Cleaved PARP (left) and apoptosis (right) were determined.
The data are presented as the mean ± SD of three replications. * P < 0.05, ** P < 0.01.
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MiR-487b-3p inhibits tumor growth in vivo.
To determine the function of miR-487b-3p in vivo, athymic nude mice were
subcutaneously inoculated with CBS control or miR-487b-3p-expressing cells. Xenograft
tumor growth curves indicated that tumors of control cells (designated control tumors) grew at
a significantly higher rate than those of miR-487b-3p-expressing cells (designated miR-487b3p tumors) (Fig. 4.8a). Consequently, control tumors were much bigger than miR-487b-3p
tumors (Fig. 4.8b). Analysis of GRM3 expression showed that the intensity of GRM3 staining
and percentage of GRM3 positive cells were notably lower in miR-487b-3p tumors than in
control tumors (Fig. 4.8c). Moreover, TUNEL and Ki67 staining indicated more apoptotic cells
and fewer proliferative cells in miR-487b-3p tumors than in control tumors (Figs. 4.8d & 4.8e).
These results demonstrate that miR-487b-3p suppresses GRM3 expression and inhibit tumor
growth in vivo.
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Fig 4.8

Figure 4.8. MiR-487b-3p suppresses GRM3 expression and inhibits tumor growth in
vivo. a, Xenograft tumor growth curves of CBS control and miR-487b-3p-expressing cells is
shown. n=16. b, Representative images of tumors at the endpoint of experiments are shown.
The pictures were taken on the same scale with the ruler with each tumor (Fig. S10). c,
Representative images of GRM3 staining in xenograft tumors are shown (upper).
Quantification of staining intensity and percentage of GRM3 positive cells was performed
(lower). d&e, Representative images of TUNEL (d) and Ki67 (e) staining are shown (left).
Percentage of positive TUNEL (d) and Ki67 (e) staining cells were determined (right). Scale
bars, 100 µm. The data are presented as the mean ± SD. *P < 0.05, ** P < 0.01. f, A proposed
model of crosstalk between miR-487b-3p, GRM3 and TGFβ signaling in regulation of
PKA/AKT activation, cell survival, proliferation and tumorigenesis of colon cancer cells.
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Expression of miR-487b-3p is decreased in colon cancer specimens.
To explore clinical relevance of miR-487b-3p, its expression was determined by in situ
hybridization in the same sets of TMAs utilized in Figure 1. The staining intensity of miR487b-3p was much stronger in miR-487b-3p-expressing tumors than in control tumors (Fig.
4.9a), verifying the specificity of the probe. Analysis of TMAs indicated that miR-487b-3p
expression was very high in normal colon epithelium, but decreased markedly in colon tumors
(Fig. 4.9b). Quantification of staining showed that the average intensity was significantly lower
in colon adenocarcinomas than in normal colon (Fig. 4.9c), which is consistent with results
from TCGA databases (Fig. 4.11). In addition, the correlation study revealed a significant
inverse correlation between miR-487b-3p and GRM3 expression (Fig. 9d, *** P = 0.0003).
These results demonstrate that miR-487b-3p expression is decreased in colon adenocarcinomas
and that miR-487b-3p expression is inversely correlated with GRM3 expression.
Taken together, our studies suggest a novel model of crosstalk between miR-487b-3p,
GRM3 and TGFβ signaling (Fig. 4.8f). In this model, while miR-487b-3p inhibits GRM3
translation, TGFβ increases GRM3 protein stability as a negative feedback mechanism to
antagonize TGFβ-induced PKA activation, AKT inhibition and suppression of cell survival,
proliferation and tumorigenesis. Therefore, inhibition of GRM3 or expression of miR-487b-3p
prevents this negative feedback and enhances TGFβ-mediated tumor suppressor function.
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Fig 4.9

Figure 4.9. Expression of miR-487b-3p is decreased in colon cancer specimens. In situ
hybridization analysis of miR-487b-3p was performed in xenograft tumors and human
specimens. a, Representative images of miR-487b-3p staining in xenograft tumors are shown.
Scale bars, 100 µm. b, Normal colon in the absence of the probe was used as a negative control.
Representative images of miR-487b-3p staining in normal colon and colon tumors are shown.
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Scale bars, 100 µm. c, Quantification of the staining intensity was performed. The values of
individual samples are shown. Error bars indicate SEM of the values. ** P < 0.01. d, Correlation
of expression of miR-487b-3p and GRM3 was determined using Pearson's test (r = -0.439, ***
P = 0.0003; n = 64). The slope was generated by lineage regression analysis.
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Fig 4.10
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Fig. 4.10. FET cells were transfected with miR-487b-5p mimic. GRM3 expression was
determined by western blot analysis.
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Fig 4.11

Fig. 4.11. Comparison of miR-487b-3p expression between normal colon and colon tumor
samples was performed by analyzing UNC-H_miRNA 8X15K level 3 dataset from TCGA
database. The difference between two groups was evaluated by 2 tail student t test (*** P <
0.001).
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Fig 4.12

GRM4
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Fig. 4.12. RT-PCR analysis of GRM4 mRNA expression in HCECs and colon cancer cell lines.
Mouse brain tissues were used as a positive control.
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Fig 4.13

Fig. 4.13. a, Comparison of percentage of GRM3 positive cells in well-, moderately- and
poorly-differentiated colon tumors. The values of individual samples are shown. Error bars
indicate SEM of the values. * P < 0.05. b, Immunohistochemistry staining of GRM3 was
performed in normal pancreas and pancreatic tumors. Representative images are shown. Scale
bars, 100 µm. c, Quantification of GRM3 staining intensity (left) and percentage of GRM3
positive cells (right) was performed. The values of individual samples are shown. Error bars
indicate SEM of the values. *** P < 0.001.
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Fig 4.14

Fig. 4.14. Western blot analysis of pERK and ERK in GRM3 knockdown (a) and miR-487b3p-expressing cells (b).
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Fig 4.15

Fig. 4.15. a. Control and GRM3 knockdown cells were treated with 5 ng/ml BMP.
Phosphorylation of Smad1/5 was determined. b, FET and HCT116 cells were treated with 5
ng/ml BMP. Expression of GRM3 was determined.
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DISCUSSION
Although GRM3 protein expression is considerably higher in colon adenocarcinomas than
in normal colon (Fig. 4.1), analysis of TCGA databases reveals that GRM3 mRNA remains
unchanged (data not shown). It suggests that GRM3 upregulation is mediated at the
posttranscriptional level. While transcriptional regulation of GRM3 has been reported

155-157

,

our findings that miR-487b-3p directly targets GRM3 to suppress its translation and that TGFβ
increases GRM3 protein stability provide novel mechanisms of posttranscriptional regulation
of GRM3 in colon cancer. Of note, GRM2, the other group II metabotropic glutamate receptor,
and GRM4, reported to be present in colon cancer cells118, are barely expressed in colon cancer
cells used in the study (Fig. 4.2a and Fig. 4.12), suggesting that they may not play a role in
colon cancer.
When correlating GRM3 expression with clinicopathological features of tumors, no
significant correlation was found between GRM3 expression and tumor grades or stages (data
not shown). However, percentage of GRM3 positive cells is noticeably higher in poorlydifferentiated tumors than moderately-differentiated ones (Fig. 4.13a). Due to small sample size
of well-differentiated tumors, the difference between well-differentiated tumors and
moderately- or poor-differentiated ones is not significant. In addition, GRM3 expression is
significantly higher in pancreatic tumors than in normal pancreas (Fig. 4.13b and 4.13c),
indicating that upregulation of GRM3 expression is not specific to colon cancer.
It has been shown that mGluRs, such as GRM1 and mutant GRM3, activate the MEK
pathway in nervous and melanoma cells

77,117

. In this study, we show that GRM3 knockdown

activates PKA and inhibits AKT in colon cancer cells. In addition, GRM3 knockdown or
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overexpression of miR-487b-3p also decreases ERK activity (Fig. 4.14). It indicates that GRM3
can activate multiple cancer-related signaling pathways and that the components of the
glutamatergic system are active in colon cancer cells. Although we show that GRM2 expression
is not upregulated in colon cancer cells, it remains to be determined whether other glutamate
receptors or other elements of glutamate signaling are aberrantly expressed in colon cancer.
Our studies indicate that GRM3 antagonizes TGFβ-mediated tumor suppressor effect and
that TGFβ increases GRM3 protein stability in a Smad2/3-dependent manner. These results
suggest that there is a negative feedback regulation between GRM3 and TGFβ signaling (Fig.
4.8f). This is of significance since TGFβ is a major tumor suppressor in colon cancer. The
negative feedback regulation between TGFβ and GRM3 could potentially prevent efficient
intervention of tumor growth and progression by TGFβ signaling. In addition, it will be
interesting to investigate whether TGFβ increases GRM3 expression in cancers where TGFβ
functions as a tumor promoter (i.e. breast cancer). If so, given that GRM3 activates AKT and
MEK signaling pathways, GRM3 could potentially contribute to TGFβ-mediated tumor
promoting function (i.e. EMT, etc). Therefore, inhibition of GRM3 could not only enhance
TGFβ-mediated tumor suppressor function but also counteract TGFβ-mediated tumor
promoting function, making targeting GRM3 an efficient anti-cancer approach despite of dual
function of TGFβ signaling. Furthermore, GRM3 can also function independently of TGFβ
signaling since GRM3 knockdown in HCT116 cells with defective TGFβ signaling increased
apoptosis and reduced anchorage-independent growth (Fig. 4.2). Hence, GRM3 can be a
promising molecular target in colon cancer defective of TGFβ signaling, which occurs in 3040% of colon cancer patients.
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It has been reported that GRM3 negatively regulates BMP signaling in glioma cells
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.

However, we found that GRM3 knockdown did not activate BMP signaling in colon cancer
cells (Fig. 4.15a). In addition, unlike TGFβ, BMP treatment did not increase GRM3 expression
(Fig. 4.15b). These results suggest that BMP signaling is not likely involved in the effects
mediated by GRM3 knockdown and in the regulation of GRM3 expression.
Taken

together,

we

have

identified

a

signaling

axis,

miR-487b-

3p/GRM3/TGFβ/PKA/AKT, as an important regulator of tumorigenesis in colon cancer. Our
studies suggest that GRM3 could be a novel molecular target for colon cancer treatment.
However, one concern to target glutamate signaling for cancer treatment is whether it would
affect brain or neuron function. A significant amount of work has gone into designing and
testing of drugs to modulate glutamatergic system to treat neurological and psychiatric
disorders. Pharmaceutical companies have generated libraries of compounds that are not
optimal for treating neuropsychiatric disorders due to problems such as inability to readily
penetrate blood brain barriers. However, those compounds could be ideal agents for other
applications, for example, anti-cancer therapy. Since GRM3 is mainly upregulated in colon
cancer but rarely expressed in normal peripheral tissues, targeting GRM3 with such agents
would not likely cause adverse neurological or peripheral side effects, making GRM3 an
attractive and specific target for colon cancer treatment.
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CHAPTER 5 ： MICRORNA-656-3P/VGLUT3 CROSSTALKS WITH TGFΒ
SIGNALING TO REGULATE COLON CANCER TUMORIGENESIS
INTRODUCTION
Colon cancer is the second leading cause of cancer death in the US, primarily due to
metastatic disease 1(1). Treatment of metastatic colon cancer with molecule-targeting drugs has
not had a large clinical impact; therefore, there is an urgent need to identify new molecule
targets and develop novel target-specific therapies.
Glutamate is the predominant excitatory neurotransmitter in the central nervous system. In
nervous glutamate is sorted in the synaptic vesicle before release to synaptic cleft
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. In

mammals, two group of glutamate transport are responsible for maintaining glutamatergic
system, Sodium-dependent excitatory Amino Acid Transporters (EAATs) and the VGLUTs.
The family of VGLUTs is comprised of three highly homologous proteins VGLUT1-3. They
transport glutamate from the cytoplasm into the synaptic vesicles 93. In addition to the CNS,
VGLUTs can be found in peripheral nervous system and in glutamate-secreting non-neuronal
cells of different organs, such as the pineal gland 97, bone99 and testes100. It has been postulated
that the peripheral glutamatergic system may use glutamate as an intercellular messenger to
communicate with neighboring cells158.
In this study, we show for the first time that VGLUT3 expression is upregulated in human
colonic adenocarcinomas and colon cancer cell lines. Knockdown of VGLUT3 expression in
colon cancer cells reduces cell survival and anchorage-independent growth in vitro and inhibits
tumor growth in vivo. In addition, VGLUT3 antagonizes TGFβ-mediated inhibition of AKT
activation and suppression of cell survival and clonogenicity. Furthermore, VGLUT3 is a direct
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target of miR-656-3p, expression of which mimics the effects of VGLUT3 knockdown in colon
cancer cells in vitro and in vivo. Expression of miR-656-3p is downregulated in colon
adenocarcinomas and inversely correlates with VGLUT3 expression. Taken together, these
studies indicate that VGLUT3 maintains AKT activation and counteracts TGFβ signaling to
regulate colon cancer tumorigenesis. It suggests that upregulation of VGLUT3 expression is a
functionally important molecular event during colon cancer development and that VGLUT3 is
a potential molecular target for colon cancer treatment. This is especially interesting and
important from a therapeutic standpoint. Given that VGLUT3 is mainly present in CNS and
upregulated in colon cancer, but rarely expressed in normal peripheral tissues, targeting
VGLUT3 with agents that cannot penetrate blood brain barrier would therefore not likely cause
adverse neurological or peripheral side effects, making VGLUT3 an attractive and specific
target for colon cancer treatment.
RESULTS
Expression of VGLUT3 is significantly increased in colon cancer specimens.
Aberrant glutamatergic signaling has been reported to play a role in cancer 118,127. VGLUTs
are critical components in glutamatergic system. However, little is known of their expression
and function in cancer. To determine whether VGLUTs may play a functional role in colon
cancer, we examined expression of VGLUT1-3 in a panel of human colon cancer cell lines.
HCT116 and RKO cells are defective in TGFβ signaling due to the lack of TGFβ RII
expression144. HCT116b cells were isolated from the same primary colon tumor as HCT116
cells, but displayed much lower metastatic potential

145

. FET cells, isolated from a well

differentiated early stage colon tumor, are sensitive to TGFβ-mediated growth inhibition and
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apoptosis133. CBS and GEO cells are partially responsive to TGFβ due to low TGFβ RII and RI
expression, respectively 134,146. All cell lines bear either KRAS or BRAF mutations, and all of
them except RKO 148 have mutated APC or β-catenin. An immortalized human colon epithelial
cell line, HCEC 119, was included as a control. RT-PCR assays indicated that VGLUT3 mRNA
was ubiquitously expressed in HCECs and colon cancer cell lines whereas expression of
VGLUT1 and VGLUT2 mRNA was undetectable (Fig. 5.1A, left). Western blot analysis
showed that VGLUT3 protein expression was markedly higher in colon cancer cells than in
HCECs (Fig. 5.1A, right). These results indicate that VGLUT1 and VGLUT2 are not expressed
in HCECs and colon cancer cells and that VGLUT3 expression is upregulated in colon cancer
cells as compared to immortalized colon epithelial cells. Given that VGLUT3 mRNA levels
were similar between HCECs and most of colon cancer cell lines (Fig. 5.1A, left), it suggests
that upregulation of VGLUT3 may be through post-transcriptional mechanism(s).
To determine the clinical relevance and significance of VGLUT3 upregulation, we
extended our studies to patient specimens. VGLUT3 expression was determined in normal
colon and colonic adenocarcinomas using immunohistochemistry (IHC) staining. Verification
of the anti-VGLUT3 antibody is shown in Fig. 5.3C. Tissue micro-arrays (TMA) consisting of
35 normal colon and 66 colon tumors were analyzed. Mouse brain tissue was used as a positive
control. VGLUT3 expression was very low in normal colon epithelium, but increased
significantly in colon tumors (Fig. 5.1B). Quantification of the staining showed that the average
intensity of VGLUT3 staining and percentage of VGLUT3 positive cells were approximately
2.7-fold and 2.2-fold higher in tumor samples than in normal colon respectively (Fig. 5.1C).
These results demonstrate that VGLUT3 expression is upregulated in colon tumors, suggesting
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that VGLUT3 may play a functional role in colon cancer. When correlating VGLUT3
expression with clinicopathological features of tumors, no significant correlation was found
between VGLUT3 expression and tumor grade, stage and differentiation (Figure 5.9). However,
due to small sample size of certain groups, it is difficult to draw a clear conclusion.
Fig 5.1

Figure 5.1. VGLUT3 expression is elevated in colon cancer cells and patient specimens. A,
Expression of VGLUT1-3 mRNA was determined in a panel of colon cancer cell lines and
HECEs by RT-PCR assays. Mouse brain tissues were used as a positive control (left). VGLUT3
protein expression was determined by western blot analysis (right). B, Immunohistochemistry
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staining of VGLUT3 was performed in normal colon and colon adenocarcinomas. Mouse brain
tissues stained with the anti-VGLUT3 antibody in the absence or presence of a specific blocking
peptide were used as a positive and negative control respectively. Representative images are
shown. Scale bars, 100 µm. C, Quantification of VGLUT3 staining intensity (left) and
percentage of VGLUT3 positive cells (right) was performed. The values of individual samples
are shown. Error bars indicate SEM of the values. * P < 0.05, ** P < 0.01.
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Knockdown of VGLUT3 expression decreases cell survival and clonogenicity of colon
cancer cells and enhances TGFβ effect.
To determine whether upregulation of VGLUT3 plays an important role in colon cancer,
VGLUT3 expression was knocked down in FET, CBS and HCT116, three colon cancer cell
lines with different genetic background. Each of two independent shRNAs (sh2 and sh3)
reduced VGLUT3 expression markedly as compared to a scrambled shRNA control, but had no
effect on VGLUT1 and VGLUT2 expression (Fig. 5.2A and Fig. 5.10A). Knockdown of
VGLUT3 expression led to increased sensitivity to growth factor deprivation stress (GFDS)induced apoptosis, reflected by enhanced PARP cleavage (Fig. 5.2B) and 61% to 2.3-fold
increase of apoptosis detected in DNA fragmentation assays (Fig. 5.2C). In addition, soft agar
assays showed that reduction of VGLUT3 expression led to 34-46% decrease in colony
formation under anchorage-independent conditions (Fig. 5.2D). These results demonstrate that
downregulation of VGLUT3 expression decreases cell survival and clonogenecity in vitro.
We next determined the underlying mechanisms of VGLUT3 function. It has been shown
that glutamatergic signaling mediates the MAPK/ERK and PI3K/AKT pathways 103. Therefore,
activation of ERK and AKT was determined using phosphorylation of ERK (pERK) and
phosphorylation of AKT (pAKT) as respective indicators. Knockdown of VGLUT3 in FET,
CBS and HCT116 cells resulted in decreased pAKT (Fig. 5.2E and 2F). However, it had no
effect on pERK (Fig. 5.10B). These results indicate that VGLUT3 expression is involved in the
activation of AKT, which is an important survival factor in colon cancer cells 133,159.
It has been shown that TGFβ signaling activates PKA, which inhibits AKT activation and
cell survival in colon cancer cells 151. Although knockdown of VGLUT3 expression decreased
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pAKT, it did not affect CREB phosphorylation (Fig. 5.10C), indicating that the effect of
VGLUT3 on AKT activation is independent of PKA. Since knockdown of VGLUT3 and TGFβ
signaling inhibit activation of AKT independently, we determined whether combination of both
would further repress AKT activation. The results showed that concomitant VGLUT3
knockdown and TGFβ treatment led to a greater decrease in pAKT than seen with either
treatment alone (Fig. 5.2E). When cells were treated with TGFβ under GFDS for 14 hours,
TGFβ had little effect in control cells but induced apoptosis in VGLUT3 knockdown cells (Fig.
5.2G and 2H). In addition, knockdown of VGLUT3 also sensitized FET cells to TGFβ-mediated
inhibition of anchorage-independent growth (Fig. 5.2I). Taken together, these results indicate
that, in addition to activating AKT, VGLUT3 also antagonizes TGFβ-mediated tumor
suppressor function and that knockdown of VGLUT3 enhances TGFβ effects.
Fig 5.2
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Figure 5.2. Knockdown of VGLUT3 sensitizes colon cancer cells to stress-induced
apoptosis and enhances TGFβ effect. A, VGLUT3 expression was knocked down by two
shRNAs in FET, CBS and HCT116 cells. B & C, Control or VGLUT3 knockdown cells were
subjected to GFDS for indicated time. Western blot analysis of PARP cleavage (B) and DNA
fragmentation assays (C) were performed. D, Colony numbers were determined in soft agarose
assays of control or VGLUT3 knockdown cells. E, Western blot analysis showed pAKT and
AKT in FET control and VGLUT3 knockdown cells treated with 4 ng/ml of TGFβ. F,
Expression of pAKT and AKT in CBS and HCT116 control and VGLUT3 knockdown cells.
G&H, FET control or VGLUT3 knockdown cells were treated with 4 ng/ml TGFβ under GFDS
for 14 hrs. Cleaved PARP (G) and apoptosis (H) were determined. I, Colony numbers were
determined in soft agarose assays of FET control or VGLUT3 knockdown cells treated with 0.5
ng/ml TGFβ. The data are presented as the mean ± SD of three replications. * P < 0.05, ** P <
0.01.
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VGLUT3 plays a critical role in tumor growth in vivo.
To determine VGLUT3 function in tumor growth in vivo. athymic nude mice were injected
with HCT116 cells stably expressing a scrambled shRNA or VGLUT3 shRNAs. Xenograft
tumor growth curves showed that tumors of VGLUT3 shRNA-expressing cells (designated
VGLUT3 shRNA tumors) grew at a significantly lower rate than those of control cells
(designated control tumors) (Fig. 5.3A). Consequently, VGLUT3 shRNA tumors were much
smaller than control tumors (Fig. 5.3B). IHC staining confirmed knockdown of VGLUT3
expression in VGLUT3 shRNA tumors and verified the specificity of the anti-VGLUT3
antibody (Fig. 5.3C). TUNEL and Ki67 staining showed much more apoptotic cells and fewer
proliferative cells in VGLUT3 shRNA tumors than in control tumors (Fig. 5.3D). These results
indicate that knockdown of VGLUT3 inhibits tumor growth in vivo and that this inhibitory
effect is a combined result of increased apoptosis and suppressed proliferation.
Fig 5.3
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Figure 3. VGLUT3 mediates tumor growth of colon cancer cells in vivo. A, Xenograft tumor
growth curves of HCT116 control and VGLUT3 shRNA-expressing cells are shown. n=16. B,
Images of tumors at the endpoint of experiments are shown. Scale bars, 1 cm. C, Representative
images of VGLUT3 staining in xenograft tumors are shown (upper). Quantification of staining
intensity was performed (lower). D, Representative images of TUNEL and Ki67 staining are
shown (upper). Percentage of positive staining cells was determined (lower). Scale bars, 100
µm. The data are presented as the mean ± SD. *P < 0.05, ** P < 0.01, *** P < 0.001.
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MiR-656-3p regulates VGLUT3 expression in colon cancer cells.
Since VGLUT3 expression may be regulated post-transcriptionally, miRNAs, functioning
as post-transcriptional regulators of mRNA expression and/or translation, could regulate its
expression. We therefore performed an in silico search for putative miRNA-binding sites in the
3’-UTR of the human VGLUT3 mRNA using TargetScan

152

, PicTar

153

and miRanda-

mirSVR154. Among miRNA candidates conserved between human and mouse, miR-656-3p was
identified as a potential regulator of VGLUT3. Q-PCR assays indicated that expression of miR656-3p was much lower in colon cancer cell lines than in HCECs (Fig. 5.4A), suggesting that
decreased miR-656-3p expression may contribute to upregulated VGLUT3 expression in colon
cancer cells.
To demonstrate that miR-656-3p regulates VGLUT3 expression, the miR-656 precursor
was stably infected into FET, CBS and HCT116 cells. As a result, expression of mature miR656-3p was significantly increased (Fig. 5.4B). Complementarily, a chemically synthesized
miR-656-3p inhibitor markedly reduced endogenous miR-656-3p expression by 40% and 43%
in FET and HCT116 cells respectively (Fig. 5.4B). Overexpression of miR-656-3p decreased
VGLUT3 protein expression (Fig. 5.4C) whereas the miR-656-3p inhibitor increased VGLUT3
protein expression (Fig. 5.4D). However, VGLUT3 mRNA expression was not affected (Fig.
5.4E). These results indicate that miR-656-3p suppresses VGLUT3 expression by inhibiting its
translation. To determine whether VGLUT3 is a direct target of miR-656-3p, three sequences
in the 3’-UTRs of VGLUT3 containing the potential miR-656-3p recognition element (Fig.
5.4F) was cloned into a luciferase construct. Luciferase assays revealed that miR-656-3p
repressed site 1 but not site 2 or site 3 of 3’-UTRs of VGLUT3 (Fig. 5.4G). These results
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indicate that miR-656-3p directly targets VGLUT3 partially through binding to site 1 to inhibit
its translation.
MiR-656-3p inhibits AKT activation and mediates stress-induced apoptosis and
clonogenicity in colon cancer cells.
Similar to VGLUT3 knockdown, miR-656-3p decreased pAKT (Fig. 5.4C) but had no
effect on ERK or PKA activation (Fig. 5.10D and 5.10E). MiR-656-3p-expressing cells
displayed increased PARP cleavage and 48-54% increase of apoptosis under GFDS (Fig. 5.5A).
In addition, anchorage-independent growth was reduced by 34-60% in miR-656-3p-expressing
cells (Fig. 5.5B). These results indicate that miR-656-3p mimics the effect of VGLUT3
knockdown. In contrast, the miR-656-3p inhibitor, which effectively inhibited miR-656-3p
expression in FET and HCT116 cells (Fig. 5.4B), reduced PARP cleavage and decreased GFDSinduced apoptosis by 34% and 54% respectively (Fig. 5.5C).
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Fig 5.4

Figure 5.4. VGLUT3 is a direct target of miR-656-3p. A, Expression of miR-656-3p was
determined in HCECs and colon cancer cells by Q-PCR assays. B, Expression of miR-656-3p
was determined after infection with miR-656 precursor or transfection with the miR-656-3p
inhibitor. C&D, VGLUT3 expression was determined by western blot assays after infected with
the miR-656 precursor (C) or transfected with the miR-656-3p inhibitor (D). Expression of
AKT and pAKT was also determined. E, mRNA expression of VGLUT3 was determined by
RT-PCR assays after infected with miR-656 precursor or transfected with the miR-656-3p
inhibitor. F, The predicted miR-656-3p recognition sites in the 3’-UTR of VGLUT3 are
indicated by vertical lines. G, After transfection with psiCheck-2 constructs containing site 1,
2 or 3 sequences, luciferase assays were performed in FET control and miR-656-3p expressing
cells.
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To determine whether miR-656-3p-mediated sensitization to GFDS-induced apoptosis
could be reversed by restoration of VGLUT3 expression, VGLUT3 cDNA was infected into
miR-656-3p-expressing FET and HCT116 cells (Fig. 5.5D, upper). Ectopically expressed
VGLUT3 is resistant to down-regulation mediated by miR-656-3p due to the lack of 3’-UTR.
Ecotopic VGLUT3 expression reversed miR-656-3p-mediated increase of apoptosis under
GFDS (Fig. 5.5D). These results indicate that miR-656-3p sensitizes colon cancer cells to
GFDS-induced apoptosis through the down- regulation of VGLUT3 expression.
To investigate whether miR-656-3p enhances TGFβ-mediated tumor suppressor function,
FET cells were treated with TGFβ under GFDS for 14 hours. TGFβ induced apoptosis in miR656-3p-expressing cells but not in control cells (Fig. 5.5E). In addition, TGFβ inhibited
anchorage-independent growth by 61% in miR-656-3p-expressing cells but only by 30% in
control cells (Fig. 5.5F). Complementarily, FET cells were treated with TGFβ under GFDS for
24 hours. While TGFβ induced apoptosis in control cells, the miR-656-3p inhibitor significantly
attenuated TGFβ-induced apoptosis (Fig. 5.5G). These results indicated that miR-656-3p
enhances TGFβ-induced apoptosis and that inhibition of miR-656-3p antagonizes TGFβ effect.
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Fig 5.5

Figure 5.5. MiR-656-3p mimics the effect of VGLUT3 knockdown in colon cancer cells. A,
Vector- or miR-656-3p-expressing FET, CBS and HCT116 cells were subject to GFDS for
indicated time. Cleaved PARP (left) and apoptosis (right) were determined. B, Colony numbers
were determined in soft agarose assays of vector- or miR-656-3p-expressing cells. C, FET and
HCT116 cells transfected with the miR-656-3p inhibitor were subjected to GFDS for 24 or 72
hrs respectively. Western blot analysis of cleaved PARP (left) and DNA fragmentation assays
(right) were determined. D, VGLUT3 was ectopically expressed in miR-656-3p-expressing
FET and HCT116 cells (upper), which were subjected to GFDS for 24 and 72 hrs respectively.
Cleaved PARP (upper) and apoptosis (lower) were determined. E, Vector- or miR-656-3pexpressing FET cells were treated with 4 ng/ml TGFβ under GFDS for 14 hrs. Cleaved PARP
(left) and apoptosis (right) were determined. F, Colony numbers were determined in soft
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agarose assays of vector- or miR-656-3p-expressing FET cells treated with 0.5 ng/ml TGFβ. G,
FET cells transfected with the miR-656-3p inhibitor were treated with 4 ng/ml TGFβ under
GFDS for 24 hrs. Cleaved PARP (left) and apoptosis (right) were determined. The data are
presented as the mean ± SD of three replications. * P < 0.05, ** P < 0.01, *** P < 0.001.
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MiR-656-3p inhibits tumor growth in vivo.
We next determine the function of miR-656-3p in vivo. Athymic nude mice were
subcutaneously inoculated with HCT116 control or miR-656-3p-expressing cells. Xenograft
tumor growth curves showed that tumors of miR-656-3p-expressing cells (designated miR-6563p tumors) grew at a significantly lower rate than those of control cells (designated control
tumors) (Fig. 5.6A). Consequently, miR-656-3p tumors were much smaller than control tumors
(Fig. 5.6B). Analysis of VGLUT3 expression showed that the intensity of VGLUT3 staining
was notably lower in miR-656-3p tumors than in control tumors (Fig. 5.6C). Furthermore,
TUNEL and Ki67 staining indicated more apoptotic cells and fewer proliferative cells in miR656-3p tumors than in control tumors (Fig. 5.6D). These results demonstrate that miR-656-3p
suppresses VGLUT3 expression, increases apoptosis, decreases proliferation and inhibit tumor
growth in vivo.
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Fig 5.6

Figure 5.6. MiR-656b-3p suppresses VGLUT3 expression and inhibits tumor growth in
vivo. A, Xenograft tumor growth curves of HCT116 control and miR-656-3p-expressing cells
is shown. n=16. B, Images of tumors at the endpoint of experiments are shown. Scale bars, 1
cm. C, Representative images of VGLUT3 staining in xenograft tumors are shown (left).
Quantification of staining intensity was performed (right). D, Representative images of TUNEL
and Ki67 staining are shown (left). Percentage of positive TUNEL and Ki67 staining cells were
determined (right). Scale bars, 100 µm. The data are presented as the mean ± SD. *P < 0.05,
** P < 0.01.
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Expression of miR-656-3p is decreased in colon cancer specimens.
To explore clinical relevance of miR-656-3p, its expression was determined by in situ
hybridization in the same sets of TMAs utilized in Figure 1. The staining intensity of miR-6563p was much stronger in miR-656-3p-expressing tumors than in control tumors (Fig. 5.7A),
verifying the specificity of the probe. Analysis of TMAs indicated that miR-656-3p expression
was high in normal colon epithelium, but decreased markedly in colon tumors (Fig. 5.7B).
Quantification of staining showed that the average intensity was significantly lower in colon
adenocarcinomas than in normal colon (Fig. 5.7C). In addition, the correlation study revealed
a moderate negative correlation between miR-656-3p and VGLUT3 expression (Fig. 5.7D, *P
= 0.025). These results demonstrate that miR-656-3p expression is decreased in colon
adenocarcinomas and inversely correlates with VGLUT3 expression and that downregulation
of miR-656-3p in colon tumors is at least partially responsible for VGLUT3 upregulation.

85

Fig 5.7

Figure 5.7. Expression of miR-656-3p is decreased in colon cancer specimens. In situ
hybridization analysis of miR-656-3p was performed in xenograft tumors and human
specimens. A, Representative images of miR-656-3p staining in xenograft tumors are shown.
Scale bars, 100 µm. B, Normal colon in the absence of the probe was used as a negative control.
Representative images of miR-656-3p staining in normal colon and colon tumors are shown.
Scale bars, 100 µm. C, Quantification of the staining intensity was performed. The values of
individual samples are shown. Error bars indicate SEM of the values. *** P < 0.001. D,
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Correlation of expression of miR-656-3p and VGLUT3 was determined in colon tumors using
Pearson's test (r = -0.3, * P = 0.025; n = 59). The slope was generated by lineage regression
analysis.
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Taken together, our studies suggest a novel model of crosstalk between miR-656-3p,
VGLUT3, AKT and TGFβ signaling (Fig. 5.8). In this model, miR-656 downregulates
VGLUT3 expression, which leads to AKT inhibition. On the other hand, TGFβ signaling
activates PKA and suppresses AKT activation. Consequently, downregulation of VGLUT3 or
expression of miR-656-3p collaborates with TGFβ signaling to inhibit AKT activation and
enhance TGFβ-mediated tumor suppressor function whereas upregulation of VGLUT3
expression antagonizes TGFβ signaling to promote proliferation, survival and tumorigenesis.

Fig 5.8

Figure 5.8. A proposed model of crosstalk between miR-656-3p, VGLUT3 and TGFβ signaling
in regulation of AKT activation, cell survival, proliferation and tumorigenesis of colon cancer
cells.
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Fig 5.9

Fig. 5.9. Comparison of VGLUT3 intensity and percentage of VGLUT3 positive cells was
made in low, moderate and high grade colon tumors (A), in different stages of colon tumors (B)
and in well-, moderately- and poorly-differentiated colon tumors (C). The values of individual
samples are shown. Error bars indicate SEM of the values. There is no significant difference
among the groups.
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Fig 5.10

Fig. 5.10. A, RT-PCR analysis of VGLUT1-3 mRNA expression in VGLUT3 knockdown FET
cells. Mouse brain tissues were used as a positive control. B&D, Western blot analysis of pERK
and total ERK in VGLUT3 knockdown cells (B) and miR-656-3p expressing cells (D). C&E,
Western blot analysis of pCREB and total CREB in VGLUT3 knockdown cells (C) and miR656-3p expressing cells (E).
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Fig 5.11

Fig. 5.11. Glutamate secretion was evaluated in the control and VGLUT3 knockdown cells.
Cells were cultured in glutamine-free, glutamate-free and phenol red-free DMEM (Gibco) for
48 hours. Conditioned medium was collected and glutamate levels were determined using
AMPLEX Red Glutamic Acid assay kit (Invitrogen) and analyzed on a fluorescence plate reader.
The average concentrations of glutamate per 10,000 cells are shown. Error bars indicate SD of
the values. There is no significant difference among the groups.
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DISCUSSION
Glutamatergic signaling has been extensively studied in nerve cells, where they modulate
excitatory synaptic transmission. VGLUT3, a vesicular glutamate transporter, is an unusual
member of the VGLUT family. It is expressed not only in glutamatergic neurons but also in
non-glutamatergic neurons such as serotonergic and cholinergic neurons and in astrocytes as
well. In addition, its subcellular localization is not restricted to synaptic boutons, but also
includes the cell soma and dendrites 95,96. In this study, we discover that expression of VGLUT3
is upregulated significantly in colon tumors as compared to normal colon. Additional findings
indicate that miR-656-3p directly targets VGLUT3 to suppress its translation and that
downregulation of miR-656-3p in colon tumors is at least partially responsible for VGLUT3
upregulation. Therefore, our studies provide a novel mechanism by which VGLUT3 expression
is regulated in colon cancer. Of note, VGLUT1 and VGLUT2, two other vesicular glutamate
transporters, are barely expressed in colon cancer cells (Fig. 5.1A), suggesting that they may
not play a role in colon cancer.
It has been reported that VGLUTs transport cytoplasmic glutamate into the synaptic
vesicles, which is then released by glutamatergic neurons

93

. Outside the nervous system,

VGLUTs can be found in the glutamate-secreting non-neuronal cells of different organs, such
as the pineal gland

97

, bone

99

and testes

100

. It has been proposed that this peripheral

glutamatergic system may use glutamate as a messenger to transduce signaling in an autocrine
or paracrine manner. We have shown that GRM3, a group II metabotropic glutamate receptor,
is significantly upregulated in colon cancer and that knockdown or inhibition of GRM3
activation in colon cancer cells reduces cell survival and anchorage-independent growth in vitro
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and inhibits tumor growth in vivo

160

.

These studies suggest that peripheral glutamatergic

signaling may contribute to colon cancer development. Therefore, a potential function of
VGLUT3 in colon cancer would be to facilitate glutamate secretion, which then activates
GRM3 or other glutamate receptors to promote tumor growth. However, knockdown of
VGLUT3 expression did not affect glutamate secretion in FET and HCT116 cells (Fig. 5.11),
indicating that VGLUT3 is not involved in glutamate secretion of colon cancer cells. In addition,
glutamate signaling, for example GRM3 activation, has been shown to activate downstream
signaling pathways including PI3K/AKT and MAPK/ERK

103,160

. Although knockdown of

VGLUT3 inhibits AKT activation, it has no effect on ERK activity (Fig. 5.10B). It remains to
be determined whether VGLUT3 contributes to glutamatergic signaling and how VGLUT3
regulates AKT activation in colon cancer cells.
Our studies indicate that VGLUT3 antagonizes TGFβ-mediated tumor suppressor effect.
This is of significance since TGFβ is an important tumor suppressor in colon cancer

132-135

.

Upregulation of VGLUT3 could potentially prevent efficient intervention of tumor growth and
progression by TGFβ signaling. TGFβ has been shown to activate PKA, which subsequently
inhibits AKT activation in colon cancer cells

159

. However, knockdown of VGLUT3 has no

effect on PKA signaling, but represses AKT activation. Therefore, VGLUT3 and TGFβ
signaling counteract each other to regulate AKT activity (Fig. 5.8). Furthermore, VGLUT3 can
also function independently of TGFβ signaling since knockdown of VGLUT3 in HCT116 cells
with defective TGFβ signaling led to decreased AKT activation, increased apoptosis and
reduced anchorage-independent growth (Fig. 5.2). Therefore, VGLUT3 is a potential molecular
target in colon cancer regardless of the status of TGFβ signaling. In addition, VGLUT3
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expression is also markedly higher in pancreatic tumors than in normal pancreas (data not
shown), indicating that upregulation of VGLUT3 expression is not specific to colon cancer and
that VGLUT3 could be a prospective therapeutic target in other cancers as well.
Taken together, we have identified a signaling axis, miR-656-3p/VGLUT3/AKT, as an
important regulator of tumorigenesis in colon cancer. Our studies suggest that VGLUT3 could
be a novel molecular target for colon cancer treatment. Therefore, development of VGLUT3
inhibitors that cannot cross blood brain barriers is of clinical significance. Since VGLUT3 is
mainly expressed in CNS and upregulated in colon cancer but rarely expressed in normal
peripheral tissues, targeting VGLUT3 with those inhibitors will not likely cause adverse
neurological or peripheral side effects, making VGLUT3 an attractive and specific target for
colon cancer treatment.
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CHAPTER 6: DISCUSSION AND FUTURE DIRECTIONS
miRNAs and TGFβ
In this study, we identified several miRNAs whose expression is either downregulated or
upregulated after TGFβ treatment in a functional screening. We confirmed that miR-487b-3p
and miR-656-3p modulated TGFβ function in colon cancer cells. TGFβ signaling plays multiple
roles in different stages of cancer. During tumor progression, there are many genetic events
occur in TGFβ signaling pathway, including the mutations of TGFβ receptor RII as well as
SMAD proteins

24 31

. However, those changes cannot fully explain the alterations in TGFβ

signaling during tumor progression. miRNAs are important regulators of TGFβ, they modulate
TGFβ function by targeting canonical TGFβ signaling components or regulating TGFβ target
genes74. Both miR-487b-3p and miR-656-3p enhance TGFβ function by inhibiting AKT
activation. However, they have no effect on canonical TGFβ signaling itself. MiR-487b-3p and
miR-656-3p are both located at 14q32.31 locus. By analyzing TCGA data base, we found that
loss of copy number of this region was frequently occurred in colon cancer (data not shown).
Those data suggest that during cancer progression, decrease of those two miRNAs may
contribute to attenuated TGFβ tumor suppressing effect in colon cancer. By analyzing the target
genes of those miRNAs, we will be able to identify novel regulators of TGFβ signaling and
tumor growth.
Regulation of glutamate homeostasis in cancers
We have demonstrated that expression of GRM3 and VGLUT3 was increased in colon
cancer patient samples and both of them played important roles in tumorigenesis of colon cancer.
GRM3 and VGLUT3 are both key components of glutamatergic signaling. Two decades ago,
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people noticed that glutamate level was increased in colon cancer tissues

161

. Glutamate is a

major product of glutaminolysis in mammalian cells. Tumor cells use glutamine as a major fuel
for their bioenergetic needs and intermediates for macromolecular synthesis. When transported
into the cells, glutamine is rapidly converted into glutamate by phosphate-dependent
glutaminase (GLS), which consequentially, provides materials to meet cell’s energy and
biosynthetic needs 162. There are many glutamate transporters that maintain intracellular and
extracellular glutamate homeostasis. EAATs transport L-and D-aspartate along with glutamate
from extracellular environment to the cells and maintain low level of extracellular glutamate
163

. Another transporter, Na+-independent cystine/glutamate exchanger, System xc

uptakes extracellular cysteine and exports intracellular glutamate outside of the cells

−

(SXC),

164

.

In

neurons, cytoplasmic glutamate is transported into vesicles by VGLUTs, and released into
synaptic cleft 93. In tumors, loss of glutamate homeostasis is usually attributed to abnormal
expression of glutamate transporters 165. In this study, we found VGLUT3 was upregulated in
colon cancer cells. However, knockdown of VGLUT3 did not change the extracellular
glutamate level. Since the other two vesicular glutamate transporters, VGLUT1 and VGULT2,
are barely expressed in colon cancer cells, other types of transporters may play major role in
the increased level of extracellular Glutamate. People found EAAT2 mediated glutamate
transportation was

defect in glioma tissues166. In breast cancer, high level of glutamate

secretion is mediated by System xc – 167. In colon cancer cells, downregulation of EAAT1 and
EAAT3 were found to be correlated with drug resistance

168

. Therefore, it will be very

interesting to find out whether EAATs and SXC are abnormally expressed in colon cancers.
Studying their function will help understand the regulation and function of the glutamate
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pathway during tumor development.
Glutamate activates multiple pathways through multiple receptors
Glutamate is a major excitatory neurotransmitter in central nervous system. In cancers,
increasing evidence is showing its important role in tumor development. Like growth factors,
glutamate acts through binding to a large family of receptors to active multiple downstream
pathways. There are two types of glutamate receptors, ionotropic glutamate receptors and
metabotropic glutamate receptors, both families have been proven to foster tumor growth in
different cell context

102

. We found that knockdown of GRM3 inhibits AKT activation and

inhibits tumor growth of colon cancer cells both in vitro and in vivo. In addition, knockdown of
GRM3 also inhibits ERK activation. Those results indicate GRM3 activates multiple
downstream pathways to regulate colon cancer tumor growth. However, GRM2 and GRM4 are
absent in our cell model and do not appear to play any role. Considering that there are more
than 20 glutamate receptors, future efforts will determine the function of those receptors in
colon cancer.
Regulation of GRM3
We showed that GRM3 was upregulated in colon cancer and that the upregulation was at
the posttranscriptional level. We also showed that TGFβ increased GRM3 protein stability in a
Smad2/3-dependent manner. How GRM3 is upregulated during tumor progression remains an
interesting question. For most GPCRs, the endocytic pathway tightly controls their activity 169.
On the cell surface, GPCRs are able to bind their ligands and activate signaling cascades inside
the cells. After that, receptors are first phosphorylated by GPCR kinases (GRKs) and then
internalized, which is mediated by arrestins and clathrin-coated pits. Some of the receptors are
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recycled back to cell membrane and others are targeted to the lysosome for degradation, which
results in the complete termination of receptor activity

169

. Whether GRM3 turnover is

dysregulated in colon cancer remains to be investigated. Defects of the recycling machinery
will lead to increased expression of GRM3 on the cell surface and prolonged receptor activity.
Other insights of VGLUT3 and GRM3
VGLUTs are responsible for transporting glutamate into synaptic vesicles93. In this study,
we found that VGLUT3 was upregulated in colon cancer, leading to increased AKT activation.
It suggests the importance of glutamate transportation in cancer development. Surprisingly,
knockdown of VGLUT3 in colon cancer cells does not affect the extracellular glutamate level,
indicating that there may be other mechanisms involved in the function of VGLUT3. In
pancreatic β cells, it was found that VGLUT3 mediated glutamate uptake into insulin containing
secretory vesicles 170, which modulated insulin release 171. Those findings reveal that VGLUT3
may co-transport other growth factors through the glutamate-containing vesicles. Once released
to the extracellular environment, those growth factors may bind to their receptors and active
various downstream signaling in cancer cells.
Like other G protein coupled receptors, GRM3 converts extracellular signals into
intracellular responses. However, some G protein coupled receptors are found to be localized
on intracellular membranes, and their function is distinct from their cell surface counterparts.
For example, more than 80% of GRM5 was found at intracellular membrane in the rat and
monkey substantia nigra

172

. Only intracellular mGluR5 is able to phosphorylate ERK1/2 and

Elk-1173. Those findings emphasize that glutamate may activate distinct signaling pathways by
binding to intracellular glutamate receptors. So far, there is no evidence showing that GRM3 is
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exclusively expressed on the cell membrane. Therefore, it will be very interesting to determine
whether GRM3 is also expressed on the membrane of other intracellular organelles. The change
of intracellular glutamate may trigger distinct signaling pathways. Moreover, in that case,
VGLUTs may also play a role in this process by transporting glutamate from cytoplasm to
subcellular compartments, where glutamate binds to their receptors and activates intracellular
glutamate signaling.
Pharmacology of glutamate pathway inhibitors in cancer treatment
In recent years, increasing evidence shows the importance of glutamate signaling in tumor
development. Many glutamate receptor antagonists have been implicated to have potential for
cancer treatment. AMPAR/KR inhibitors, ZK 200775 and GYKI 52466 showed antiproliferative effect in glioma models102. An NMDAR antagonist, memantine has been
employed in a Phase II clinical trial now 102. The glutamate release inhibitor riluzole which is
approved by FDA for treating amyotrophic lateral sclerosis showed promising inhibitory effect
in glioma, breast cancer and prostate cancers 174. mGluRs are considered more susceptible for
anti-cancer drug design due to their structure –function relationship 60. However, clinical studies
of mGluR antagonists are still lacking. In this study, we showed that a GRM3 inhibitor,
LY341495, inhibited tumor growth of colon cancer cells in vivo. Future studies are needed to
validate the anti-cancer effect of GRM3 antagonists in clinical trials. Since GRM3 activates
multiple signaling pathways, combination of GRM3 antagonists with other drugs may help
increase their anti-tumor efficiency.
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